
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Targeted Therapies for Hereditary Peripheral Neuropathies: Systematic Review and Steps Towards a ‘treatabolome’ - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="ABCB7436925F59D33D74360041834EE4.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="iospressopenlib">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8203235/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Journal of Neuromuscular Diseases">
<meta name="citation_title" content="Targeted Therapies for Hereditary Peripheral Neuropathies: Systematic Review and Steps Towards a ‘treatabolome’">
<meta name="citation_author" content="Matthew J Jennings">
<meta name="citation_author_institution" content="Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK">
<meta name="citation_author" content="Angela Lochmüller">
<meta name="citation_author_institution" content="GKT School of Medical Education, King’s College London, London, UK">
<meta name="citation_author" content="Antonio Atalaia">
<meta name="citation_author_institution" content="Center of Research in Myology, Sorbonne Université - Inserm UMRS 974, Institut de Myologie, G.H. Pitie-Salpetriere, Paris, France">
<meta name="citation_author" content="Rita Horvath">
<meta name="citation_author_institution" content="Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK">
<meta name="citation_publication_date" content="2021 May 13">
<meta name="citation_volume" content="8">
<meta name="citation_issue" content="3">
<meta name="citation_firstpage" content="383">
<meta name="citation_doi" content="10.3233/JND-200546">
<meta name="citation_pmid" content="32773395">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8203235/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8203235/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8203235/pdf/jnd-8-jnd200546.pdf">
<meta name="description" content="Hereditary peripheral neuropathies are inherited disorders affecting the peripheral nervous system, including Charcot-Marie-Tooth disease, familial amyloid polyneuropathy and hereditary sensory and motor neuropathies. While the molecular basis of ...">
<meta name="og:title" content="Targeted Therapies for Hereditary Peripheral Neuropathies: Systematic Review and Steps Towards a ‘treatabolome’">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Hereditary peripheral neuropathies are inherited disorders affecting the peripheral nervous system, including Charcot-Marie-Tooth disease, familial amyloid polyneuropathy and hereditary sensory and motor neuropathies. While the molecular basis of ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8203235/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="8203235">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.3233/JND-200546"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/jnd-8-jnd200546.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC8203235%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/8203235/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/8203235/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC8203235/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-iospressopenlib.png" alt="IOS Press Open Library logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to IOS Press Open Library" title="Link to IOS Press Open Library" shape="default" href="https://doi.org/10.3233/JND-200546" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">J Neuromuscul Dis</button></div>. 2021 May 13;8(3):383–400. doi: <a href="https://doi.org/10.3233/JND-200546" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.3233/JND-200546</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22J%20Neuromuscul%20Dis%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22J%20Neuromuscul%20Dis%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J%20Neuromuscul%20Dis%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22J%20Neuromuscul%20Dis%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Targeted Therapies for Hereditary Peripheral Neuropathies: Systematic Review and Steps Towards a ‘treatabolome’</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jennings%20MJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Matthew J Jennings</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Matthew J Jennings</span></h3>
<div class="p">
<sup>a</sup>Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jennings%20MJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Matthew J Jennings</span></a>
</div>
</div>
<sup>a,</sup><sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lochm%C3%BCller%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Angela Lochmüller</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Angela Lochmüller</span></h3>
<div class="p">
<sup>b</sup>GKT School of Medical Education, King’s College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lochm%C3%BCller%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Angela Lochmüller</span></a>
</div>
</div>
<sup>b,</sup><sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Atalaia%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Antonio Atalaia</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Antonio Atalaia</span></h3>
<div class="p">
<sup>c</sup>Center of Research in Myology, Sorbonne Université - Inserm UMRS 974, Institut de Myologie, G.H. Pitie-Salpetriere, Paris, France
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Atalaia%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Antonio Atalaia</span></a>
</div>
</div>
<sup>c</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Horvath%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Rita Horvath</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Rita Horvath</span></h3>
<div class="p">
<sup>a</sup>Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Horvath%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Rita Horvath</span></a>
</div>
</div>
<sup>a,</sup><sup>*</sup>
</div>
<div class="cg p">Editor: <span class="name western">Gisèle Bonne</span>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup>a</sup>Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK</div>
<div id="aff2">
<sup>b</sup>GKT School of Medical Education, King’s College London, London, UK</div>
<div id="aff3">
<sup>c</sup>Center of Research in Myology, Sorbonne Université - Inserm UMRS 974, Institut de Myologie, G.H. Pitie-Salpetriere, Paris, France
</div>
<div class="author-notes p">
<div class="fn" id="fn1">
<sup>1</sup><p class="display-inline">These authors contributed equally.</p>
</div>
<div class="fn" id="cor1">
<sup>*</sup><p class="display-inline">Correspondence to: Dr. Rita Horvath, MD, PhD, Department of Clinical Neurosciences, University of Cambridge School of Clinical Medicine, John Van Geest Cambridge Centre for Brain Repair, RobinsonWay, CambridgeCB20PY, UK. E-mail: <span>rh732@medschl.cam.ac.uk</span>.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Prepublished 2020 Jul 31; Collection date 2021.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2021 – The authors. Published by IOS Press</div>
<p>This is an open access article distributed under the terms of the <a href="https://creativecommons.org/licenses/by-nc/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License</a>, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC8203235  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32773395/" class="usa-link">32773395</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background:</h3>
<p>Hereditary peripheral neuropathies are inherited disorders affecting the peripheral nervous system, including Charcot-Marie-Tooth disease, familial amyloid polyneuropathy and hereditary sensory and motor neuropathies. While the molecular basis of hereditary peripheral neuropathies has been extensively researched, interventional trials of pharmacological therapies are lacking.</p></section><section id="sec2"><h3 class="pmc_sec_title">Objective:</h3>
<p>We collated evidence for the effectiveness of pharmacological and gene-based treatments for hereditary peripheral neuropathies.</p></section><section id="sec3"><h3 class="pmc_sec_title">Methods:</h3>
<p>We searched several databases for randomised controlled trials (RCT), observational studies and case reports of therapies in hereditary peripheral neuropathies. Two investigators extracted and analysed the data independently, assessing study quality using the Oxford Centre for Evidence Based Medicine 2011 Levels of Evidence in conjunction with the Jadad scale.</p></section><section id="sec4"><h3 class="pmc_sec_title">Results:</h3>
<p>Of the 2046 studies initially identified, 119 trials met our inclusion criteria, of which only 34 were carried over into our final analysis. Ascorbic acid was shown to have no therapeutic benefit in CMT1A, while a combination of baclofen, naltrexone and sorbitol (PXT3003) demonstrated some efficacy, but phase III data are incomplete. In TTR-related amyloid polyneuropathy tafamidis, patisiran, inotersen and revusiran showed significant benefit in high quality RCTs. Smaller studies showed the efficacy of L-serine for <em>SPTLC1</em>-related hereditary sensory neuropathy, riboflavin for Brown-Vialetto-Van Laere syndrome (<em>SLC52A2/3)</em> and phytanic acid-poor diet in Refsum disease (<em>PHYH</em>).</p></section><section id="sec5"><h3 class="pmc_sec_title">Conclusions:</h3>
<p>The ‘treatable’ variants highlighted in this project will be flagged in the treatabolome database to alert clinicians at the time of the diagnosis and enable timely treatment of patients with hereditary peripheral neuropathies.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> Charcot-Marie-Tooth disease, inherited peripheral neuropathies, pharmacological, gene based treatments, clinical trials</p></section></section><section id="sec0005"><h2 class="pmc_sec_title">INTRODUCTION</h2>
<p>Rare diseases (RD) are individually rare but collectively common, affecting 6– 8% of the global population [<a href="#ref001" class="usa-link" aria-describedby="ref001">1</a>]. Their rarity poses unique problems to clinicians and their patients, resulting in significant delays in both diagnosis and treatment. One problem is that clinicians dealing with the relevant patients are largely unaware or unable to keep up with the increasing evidence base associated with these conditions. Considering that approximately 72% of rare disease cases are caused by Mendelian genetic variants [<a href="#ref002" class="usa-link" aria-describedby="ref002">2</a>], an ability to accurately and quickly inform clinicians of existing gene and variant-specific therapeutics would represent a quantum leap in clinical care. The ‘treatabolome’ project aims to systematically collate and evaluate evidence for the effectiveness of rare disease treatments to provide a database of ‘treatable’ variants. Currently, as part of the multi-national ‘Solve-RD’ project, several expert-led teams across the rare disease community are working towards building that database. This knowledgebase will be integrated into an interoperable rare disease genomics platform to facilitate clinicians’ access to the latest clinical data and enable timely treatment of rare disease patients. The first element of this project has been completed and published for congenital myasthenic syndromes [<a href="#ref003" class="usa-link" aria-describedby="ref003">3</a>], and a standardised protocol to be applied across the different arms of the treatabolome project has been submitted. We now aim to undertake an element of this project to define the treatabolome of hereditary peripheral neuropathies.</p>
<p>Hereditary peripheral neuropathies are a group of inherited disorders affecting the peripheral nervous system. These are divided into four major subgroups: hereditary sensory and motor neuropathies, distal hereditary motor neuropathies, hereditary sensory and autonomic neuropathies and more complex hereditary neuropathies. The most common form is the hereditary sensory and motor neuropathy, also known as Charcot-Marie-Tooth disease (CMT), with a prevalence of around 1/2500 [<a href="#ref004" class="usa-link" aria-describedby="ref004">4, 5</a>]. CMT can be further subdivided into demyelinating and axonal forms, depending on their pathophysiology. In demyelinating forms, myelin sheath degeneration precedes axon degeneration, whereas axon degeneration is the primary pathology in axonal forms.</p>
<p>As of January 2020, 93 genes have been identified to cause CMT [<a href="#ref006" class="usa-link" aria-describedby="ref006">6</a>]. These genes cover a wide range of molecular functions and intracellular processes, which can be broadly categorised as affecting intracellular transport in the axon, organelle dynamics and protein synthesis (axonal CMT), and cellular processes causing disruption of myelin production or organisation (demyelinating CMT). Inheritance patterns include all modes of Mendelian inheritance, maternal inheritance (mitochondrial DNA variants) and more complex patterns.</p>
<p>All CMT-related disorders are characterised by a length-dependent degeneration of the peripheral neurons and differ by the groups of neurons affected, with CMT affecting both sensory and motor neurons. Motor symptoms include weakness, atrophy or deformity, and sensory symptoms include numbness, paraesthesia or pain [<a href="#ref007" class="usa-link" aria-describedby="ref007">7</a>]. Some may involve the autonomic nervous system, resulting in features like impaired sweating, postural hypotension or insensitivity to pain [<a href="#ref007" class="usa-link" aria-describedby="ref007">7</a>]. Patients may also present with other neurological symptoms (e.g. spastic paraparesis, ataxia, cranial nerve abnormalities) and have non-neurological features (e.g. cataract, scoliosis, cardiac symptoms). It is important to note that the phenotype may be overlapping across the disease subgroups [<a href="#ref005" class="usa-link" aria-describedby="ref005">5</a>].</p>
<p>The disease typically follows a slowly progressive course. The prognosis of individuals depends on their genotype, but it is modified by other so far unknown genetic, epigenetic and environmental factors [<a href="#ref008" class="usa-link" aria-describedby="ref008">8</a>]. Curative pharmacological treatment is currently only available for some subtypes of hereditary peripheral neuropathies, but supportive management is useful in all cases. Supportive treatments involve physical therapy, occupational therapy, genetic counselling, orthotics (splints, braces, walking aids) and surgery [<a href="#ref009" class="usa-link" aria-describedby="ref009">9</a>].</p></section><section id="sec0010"><h2 class="pmc_sec_title">METHODS</h2>
<p>The systematic review was designed using Cochrane Collaboration methodology [<a href="#ref010" class="usa-link" aria-describedby="ref010">10</a>], as guided by the treatabolome project principles for generating FAIR-compliant datasets (soon to be published). Studies of randomised and non-randomised controlled trials, observational studies, case series and case reports of pharmacological treatment for patients with genetically confirmed hereditary peripheral neuropathies were considered for inclusion in the full systematic review. Reviews including systematic and expert reviews were screened for relevant primary data not included in our original search. All appropriate outcome measures clearly indicating a positive, neutral or negative (toxic) response to treatment were considered, including change in measures of muscle strength, functional ability and clinical examination results. Studies were assessed for quality using the Oxford Centre for Evidence-Based Medicine (OCEBM) 2011 Levels of Evidence [<a href="#ref011" class="usa-link" aria-describedby="ref011">11</a>] in conjunction with the Jadad scale [<a href="#ref012" class="usa-link" aria-describedby="ref012">12</a>]. All steps were carried out by two investigators (A.L. and M.J.) independently and reviewed by the expert team lead (R.H.), with regular meetings to establish consensus.</p>
<section id="sec0015"><h3 class="pmc_sec_title">Inclusion criteria</h3>
<p>The condition studied was genetically confirmed hereditary peripheral neuropathy. We considered only studies involving patients with genetically confirmed mutations in known neuropathy genes. Hereditary peripheral neuropathies diagnosed by techniques other than formal genetic testing were excluded due to the phenotypic overlap between the different types of neuropathies, which could confound clinical or electrophysiological diagnoses. Participants with any level of severity, age of onset and level of penetrance of phenotypic features were included. Pharmacological therapies or genotype-related dietary changes specifically targeting the neuropathy were included in this study. Non-pharmacological interventions such as physiotherapy, surgery and genetic counselling were excluded.</p>
<section id="sec0020"><h4 class="pmc_sec_title">Literature and trial database search</h4>
<p>Several electronic databases were searched in order to cover all available evidence regarding pharmacological treatment for hereditary peripheral neuropathies. Firstly, to discover studies of the highest OCEBM evidence levels, we searched for randomised controlled trials and systematic reviews of genetic neuropathies using the Cochrane Central Register of Controlled Trials (CENTRAL), The Cochrane Neuromuscular Disease Group Specialized Register, ClinicalTrials.gov, European Clinical Trials Database (EudraCT), WHO International Clinical Trials Registry (ICTRP) and the Centre for Reviews and Dissemination (CRD) database. Secondly, we carried out a wider search using the PubMed database, intending to capture a greater range of relevant literature. Full details of search terms and filters used for each database can be seen in the <a href="#S1" class="usa-link">Supplementary Table 1</a>. Database specific filters were applied to ensure only interventional studies with results available were included, and that major “miss-hit” diseases (e.g. Guillain-Barré syndrome) were excluded. Additionally, a filter for publication date after 01/01/1991 was applied where necessary, as causative genes for inherited peripheral neuropathies were discovered after this date [<a href="#ref013" class="usa-link" aria-describedby="ref013">13, 14</a>].</p></section></section><section id="sec0025"><h3 class="pmc_sec_title">Data selection</h3>
<p>Studies identified from each database were compiled and screened for duplicates. Our inclusion criteria progressively determined studies (1) written in English, with (2) human patients, who were (3) genetically diagnosed with (4) hereditary peripheral neuropathy, involving a (5) pharmacological intervention and which (6) declare their results. Additionally, relevant articles were extracted from the reference sections of systematic or expert reviews and screened for possible inclusion as above.</p></section><section id="sec0030"><h3 class="pmc_sec_title">Data extraction and analysis</h3>
<p>Characteristics of each study that fulfilled our inclusion criteria were captured in a standardised data extraction table (<a href="#S2" class="usa-link">Supplementary Table 2</a>). Information was collected on participants (number of participants, phenotype, age, affected gene and variant), interventions (type, dose, delivery, frequency and duration of treatment) and both molecular (biomarker) and clinical (functional) outcome measures.</p>
<p>The quality of each study was assessed using both the OCEBM 2011 Levels of Evidence and the Jadad scale, to accommodate for smaller yet higher quality studies commonly seen in rare disease research. Data extraction was carried out by A.L. and M.J., prior to second assessment by R.H. As the OCEBM and Jadad scores incorporate risk of bias in their scoring, we did not carry out a formal risk of bias assessment. We must assume a high risk of bias for all non-randomised studies, and the OCEBM and Jadad scores are correspondingly low.</p></section></section><section id="sec0035"><h2 class="pmc_sec_title">RESULTS</h2>
<p>Our search identified 2043 potentially relevant entries across all databases (<a href="#jnd-8-jnd200546-g001" class="usa-link">Fig. 1</a>). Following duplicate analysis with manual confirmation and elimination of duplicates, 1892 individual studies remained. The titles and abstracts of these studies were then screened for inclusion using the stated inclusion criteria in progressive steps (see Data Selection). 119 studies met all the criteria on initial screening, whereas 1776 studies failed to satisfy at least one aspect of the criteria (<a href="#jnd-8-jnd200546-g001" class="usa-link">Fig. 1</a>). Next, studies which passed this stage were read in full by two assessors to confirm their suitability according to the criteria, excluding a further 88 studies. The characteristics and findings of these studies were recorded in full in <a href="#S2" class="usa-link">Supplementary Table 2</a>. At this stage, systematic reviews and expert reviews included in our search were examined for any additional primary data that was missed. Then, the expert team lead (R.H.) reviewed the process and the 34 studies remained for detailed analysis. Additionally, 1 study which was not included in the original dataset was flagged for inclusion [<a href="#ref015" class="usa-link" aria-describedby="ref015">15</a>], giving a total of 36 included studies. The final studies are presented as grouped by the causative genes involved (<a href="#jnd-8-jnd200546-t001" class="usa-link">Tables 1</a>– <a href="#jnd-8-jnd200546-t003" class="usa-link">3</a>). For studies involving more than two different gene mutations, all described mutations are listed in <a href="#S1" class="usa-link">Supplementary Table 3</a>.</p>
<figure class="fig xbox font-sm" id="jnd-8-jnd200546-g001"><h3 class="obj_head">Fig.1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8203235_jnd-8-jnd200546-g001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f113/8203235/ef3a7f97614c/jnd-8-jnd200546-g001.jpg" loading="lazy" height="978" width="706" alt="Fig.1"></a></p>
<div class="p text-right font-secondary"><a href="figure/jnd-8-jnd200546-g001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Systematic Review methodology. (A) PRISMA flowchart of studies identified under the search strategy, showing filtering steps to produce study database for codification of data (B) Sankey diagram showing numbers of studies from each source and progressive exclusion of studies according to inclusion criteria.</p></figcaption></figure><section class="tw xbox font-sm" id="jnd-8-jnd200546-t001"><h3 class="obj_head">Table 1.</h3>
<div class="caption p"><p>Summary of results in Charcot-Marie-Tooth type 1A (CMT1A)</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1"><col align="justify" span="1"></colgroup>
<thead valign="top">
<tr>
<td rowspan="1" colspan="1">Gene,</td>
<td rowspan="1" colspan="1">Title</td>
<td rowspan="1" colspan="1">First Author,</td>
<td rowspan="1" colspan="1">Phenotype</td>
<td rowspan="1" colspan="1">Study</td>
<td rowspan="1" colspan="1">Number of</td>
<td rowspan="1" colspan="1">Drug</td>
<td rowspan="1" colspan="1">Duration</td>
<td colspan="2" align="center" rowspan="1">Target effect</td>
<td colspan="2" align="center" rowspan="1">Clinical effect</td>
<td rowspan="1" colspan="1">JADAD</td>
<td rowspan="1" colspan="1">OCEBM</td>
<td rowspan="1" colspan="1">UK</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Mutation</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Journal</td>
<td rowspan="1" colspan="1">target HPO</td>
<td rowspan="1" colspan="1">type</td>
<td rowspan="1" colspan="1">patients</td>
<td rowspan="1" colspan="1">name</td>
<td colspan="2" align="center" rowspan="1">(+/– / =),</td>
<td colspan="2" align="center" rowspan="1">(+/– / =),</td>
<td rowspan="1" colspan="1">score</td>
<td rowspan="1" colspan="1">score</td>
<td rowspan="1" colspan="1">License</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">(Year)</td>
<td rowspan="1" colspan="1">term(s)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td colspan="2" align="center" rowspan="1">description</td>
<td colspan="2" align="center" rowspan="1">description</td>
<td rowspan="1" colspan="1">(1– 5)</td>
<td rowspan="1" colspan="1">(1– 5)</td>
<td rowspan="1" colspan="1">(Y/N)</td>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">
<em>PMP22,</em> dup</td>
<td rowspan="1" colspan="1">Ascorbic acid for CMT type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial</td>
<td rowspan="1" colspan="1">Burns, Lancet Neurol (2009) [<a href="#ref030" class="usa-link" aria-describedby="ref030">30</a>]</td>
<td rowspan="1" colspan="1">Abnormal nerve conduction velocity</td>
<td rowspan="1" colspan="1">RCT</td>
<td rowspan="1" colspan="1">81 (42 intervention, 39 placebo)</td>
<td rowspan="1" colspan="1">Ascorbic acid</td>
<td rowspan="1" colspan="1">1 year</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">↑plasma ascorbic acid concentration</td>
<td rowspan="1" colspan="1">=</td>
<td rowspan="1" colspan="1">No significant change in median NCV, strength, function, or QoL</td>
<td rowspan="1" colspan="1">5</td>
<td rowspan="1" colspan="1">2</td>
<td rowspan="1" colspan="1">*N</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>PMP22,</em> dup</td>
<td rowspan="1" colspan="1">Effect of ascorbic acid in patients with CMT type 1A: a multicentre, randomised, double-blind, placebo-controlled trial</td>
<td rowspan="1" colspan="1">Micallef, Lancet Neurol (2009) [<a href="#ref036" class="usa-link" aria-describedby="ref036">36</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment</td>
<td rowspan="1" colspan="1">RCT</td>
<td rowspan="1" colspan="1">179 (intervention 61 dose 3 g, 56 dose 1 g, 62 placebo)</td>
<td rowspan="1" colspan="1">Ascorbic acid</td>
<td rowspan="1" colspan="1">1 year</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Not described</td>
<td rowspan="1" colspan="1">=</td>
<td rowspan="1" colspan="1">No significant change in CMTNS</td>
<td rowspan="1" colspan="1">5</td>
<td rowspan="1" colspan="1">2</td>
<td rowspan="1" colspan="1">*N</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>PMP22,</em> dup</td>
<td rowspan="1" colspan="1">Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial</td>
<td rowspan="1" colspan="1">Verhamme, BMC Med (2009) [<a href="#ref037" class="usa-link" aria-describedby="ref037">37</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment</td>
<td rowspan="1" colspan="1">RCT</td>
<td rowspan="1" colspan="1">13 (6 intervention, 7 placebo)</td>
<td rowspan="1" colspan="1">Ascorbic acid</td>
<td rowspan="1" colspan="1">1 year</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Not described</td>
<td rowspan="1" colspan="1">=</td>
<td rowspan="1" colspan="1">No significant change in median NCVs, strength, sensation, CMTNS or disability</td>
<td rowspan="1" colspan="1">5</td>
<td rowspan="1" colspan="1">2</td>
<td rowspan="1" colspan="1">*N</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>PMP22,</em> dup</td>
<td rowspan="1" colspan="1">Randomised controlled trial with ascorbic acid in CMT type 1A: results of the CMT-TRIAAL/CMT-TRAUK Ascorbic Acid in Charcot-Marie-Tooth Disease Type 1A (CMT-TRIAAL and CMT-TRAUK): A Double-Blind Randomised Trial</td>
<td rowspan="1" colspan="1">Pareyson, JPNS (2011) Pareyson, Lancet neurol (2011) [<a href="#ref036" class="usa-link" aria-describedby="ref036">36</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment</td>
<td rowspan="1" colspan="1">RCT</td>
<td rowspan="1" colspan="1">277 (138 intervention, 133 placebo)</td>
<td rowspan="1" colspan="1">Ascorbic acid</td>
<td rowspan="1" colspan="1">24 months</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Not described</td>
<td rowspan="1" colspan="1">=</td>
<td rowspan="1" colspan="1">No significant change in CMTNS</td>
<td rowspan="1" colspan="1">5</td>
<td rowspan="1" colspan="1">2</td>
<td rowspan="1" colspan="1">*N</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>PMP22,</em> dup</td>
<td rowspan="1" colspan="1">High-dosage ascorbic acid treatment in CMT type 1A: results of a randomized, double-masked, controlled trial</td>
<td rowspan="1" colspan="1">Lewis, JAMA Neurol (2013) [<a href="#ref037" class="usa-link" aria-describedby="ref037">37</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment</td>
<td rowspan="1" colspan="1">RCT</td>
<td rowspan="1" colspan="1">85 (69 intervention, 16 placebo)</td>
<td rowspan="1" colspan="1">Ascorbic acid</td>
<td rowspan="1" colspan="1">2 years</td>
<td rowspan="1" colspan="1">=</td>
<td rowspan="1" colspan="1">No change in <em>PMP22</em> mRNA levels</td>
<td rowspan="1" colspan="1">=</td>
<td rowspan="1" colspan="1">No significant change in CMTNS</td>
<td rowspan="1" colspan="1">5</td>
<td rowspan="1" colspan="1">2</td>
<td rowspan="1" colspan="1">*N</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>PMP22,</em> dup</td>
<td rowspan="1" colspan="1">Phase II, Randomized, Placebo-controlled Trial in Patients With CMT type 1A</td>
<td rowspan="1" colspan="1">ClinicalTrials.gov Identifier: <a href="https://clinicaltrials.gov/ct2/show/NCT01401257" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01401257</a> (2017) [<a href="#ref038" class="usa-link" aria-describedby="ref038">38</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment</td>
<td rowspan="1" colspan="1">RCT</td>
<td rowspan="1" colspan="1">80</td>
<td rowspan="1" colspan="1">PXT3003</td>
<td rowspan="1" colspan="1">12 months</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Not described</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">Decreased CMTNS &amp;ONLS in high dose group</td>
<td rowspan="1" colspan="1">5</td>
<td rowspan="1" colspan="1">2</td>
<td rowspan="1" colspan="1">N</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>PMP22,</em> dup</td>
<td rowspan="1" colspan="1">A multicenter, double-blind, placebo controlled, pivotal phase III study (PLEOCMT) of a fixed combination of baclofen, naltrexone and sorbitol (PXT3003), for the treatment of CMT1A</td>
<td rowspan="1" colspan="1">Attarian, Muscle &amp;nerve (2017) <a href="https://clinicaltrials.gov/ct2/show/NCT02579759" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02579759</a> (2020) [<a href="#ref039" class="usa-link" aria-describedby="ref039">39</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment</td>
<td rowspan="1" colspan="1">RCT</td>
<td rowspan="1" colspan="1">323</td>
<td rowspan="1" colspan="1">PXT3003</td>
<td rowspan="1" colspan="1">15 months</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Not described</td>
<td rowspan="1" colspan="1">+/=</td>
<td rowspan="1" colspan="1">Significant ↓ONLS for dose 2, non-significant ↓ONLS for dose 1</td>
<td rowspan="1" colspan="1">5</td>
<td rowspan="1" colspan="1">2</td>
<td rowspan="1" colspan="1">N</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>PMP22,</em> dup</td>
<td rowspan="1" colspan="1">Effects of exercise and creatine on myosin heavy chain isoform composition in patients with Charcot-Marie-Tooth disease</td>
<td rowspan="1" colspan="1">Smith, Muscle Nerve (2006) [<a href="#ref040" class="usa-link" aria-describedby="ref040">40</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness</td>
<td rowspan="1" colspan="1">RCT</td>
<td rowspan="1" colspan="1">18</td>
<td rowspan="1" colspan="1">Creatine monohydrate + resistance training</td>
<td rowspan="1" colspan="1">12 weeks</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">Significant decrease in MHC type I</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">↓Chair-rise-time, ↑muscle strength</td>
<td rowspan="1" colspan="1">5</td>
<td rowspan="1" colspan="1">2</td>
<td rowspan="1" colspan="1">N</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/jnd-8-jnd200546-t001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p26"><p>Summary of results in Charcot-Marie-Tooth type 1A (CMT1A). Key: + positive change, - negative change, = no change, NCV nerve conduction velocity, RCT randomised controlled trial, CMTNS Charcot-Marie-Tooth Neuropathy Score, ONLS Overall Neuropathy Limitations Scale, QoL Quality of Life, *Licensed for other indication.</p></div></div></section><section class="tw xbox font-sm" id="jnd-8-jnd200546-t003"><h3 class="obj_head">Table 3.</h3>
<div class="caption p"><p>Summary of results in other CMT subtypes and metabolic neuropathies</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="center" span="1">
<col align="center" span="1">
</colgroup>
<thead valign="top">
<tr>
<td rowspan="1" colspan="1">Gene, Mutation</td>
<td rowspan="1" colspan="1">Descriptive</td>
<td rowspan="1" colspan="1">First Author,</td>
<td rowspan="1" colspan="1">Phenotype</td>
<td rowspan="1" colspan="1">Study type</td>
<td rowspan="1" colspan="1">Drug</td>
<td colspan="2" align="center" rowspan="1">Target effect</td>
<td colspan="2" align="center" rowspan="1">Clinical effect</td>
<td rowspan="1" colspan="1">JADAD</td>
<td rowspan="1" colspan="1">OCEBM</td>
</tr>
<tr>
<td rowspan="1" colspan="1">(Ref Seq) (*see</td>
<td rowspan="1" colspan="1">name</td>
<td rowspan="1" colspan="1">Journal</td>
<td rowspan="1" colspan="1">target HPO</td>
<td rowspan="1" colspan="1">(number of</td>
<td rowspan="1" colspan="1">name</td>
<td colspan="2" align="center" rowspan="1">(+/– / =) &amp;</td>
<td colspan="2" align="center" rowspan="1">(+/– / =) &amp;</td>
<td rowspan="1" colspan="1">score</td>
<td rowspan="1" colspan="1">score</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<a href="#S1" class="usa-link">Supplement 3</a>
</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">(Year)</td>
<td rowspan="1" colspan="1">term(s)</td>
<td rowspan="1" colspan="1">patients)</td>
<td rowspan="1" colspan="1"></td>
<td colspan="2" align="center" rowspan="1">description</td>
<td colspan="2" align="center" rowspan="1">description</td>
<td rowspan="1" colspan="1">(1– 5)</td>
<td rowspan="1" colspan="1">(1– 5)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">for other</td>
<td colspan="2" align="center" rowspan="1"></td>
<td colspan="2" align="center" rowspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">mutations)</td>
<td colspan="2" align="center" rowspan="1"></td>
<td colspan="2" align="center" rowspan="1"></td>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">
<em>ELP1,</em> c.2204 + 6T&gt;C, splice site mutation (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_003640.5" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_003640.5</a>)</td>
<td rowspan="1" colspan="1">HSAN3</td>
<td rowspan="1" colspan="1">Norcliffe-Kaufmann, Neurology (2013) [<a href="#ref046" class="usa-link" aria-describedby="ref046">46</a>]</td>
<td rowspan="1" colspan="1">Nausea &amp;vomiting</td>
<td rowspan="1" colspan="1">RCT (12)</td>
<td rowspan="1" colspan="1">Carbidopa</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Not described</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">Decreased nausea &amp;retching</td>
<td rowspan="1" colspan="1">5</td>
<td rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>ELP1,</em> c.2204 + 6T&gt;C, splice site mutation (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_003640.5" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_003640.5</a>)</td>
<td rowspan="1" colspan="1">HSAN3</td>
<td rowspan="1" colspan="1">Bar-Aluma, Lung (2018) [<a href="#ref047" class="usa-link" aria-describedby="ref047">47</a>]</td>
<td rowspan="1" colspan="1">Functional respiratory abnormality</td>
<td rowspan="1" colspan="1">RCT (14)</td>
<td rowspan="1" colspan="1">Albuterol sulfate, Ipratropium bromide</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Not described</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">Increase in FEV1 &amp;FVC, decrease in airway resistance, decrease in airway obstruction</td>
<td rowspan="1" colspan="1">5</td>
<td rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>MT-ATP6,</em> m.9185T&gt;C, p.Leu220Pro (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NC_012920.1" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NC_012920.1</a>)</td>
<td rowspan="1" colspan="1">CMT2</td>
<td rowspan="1" colspan="1">Panosyan, Muscle Nerve (2017) [<a href="#ref048" class="usa-link" aria-describedby="ref048">48</a>]</td>
<td rowspan="1" colspan="1">Episodic flaccid weakness</td>
<td rowspan="1" colspan="1">Case series (2)</td>
<td rowspan="1" colspan="1">Acetazolamide</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Not described</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">Decreased frequency &amp;severity of episodic weakness</td>
<td rowspan="1" colspan="1">0</td>
<td rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>PHYH,</em> c.830 C&gt;A, p.Ala277Glu (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_001037537.1" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_001037537.1</a>)</td>
<td rowspan="1" colspan="1">Refsum disease</td>
<td rowspan="1" colspan="1">Kohlschutter, J Child Neurol (2012) [<a href="#ref030" class="usa-link" aria-describedby="ref030">30</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment, Visual impairment</td>
<td rowspan="1" colspan="1">Case study (1)</td>
<td rowspan="1" colspan="1">Phytanic acid-poor diet + extracorporeal lipid apharesis</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">Decrease in blood phytanic acid levels</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">Decrease in neurological &amp;ophthalmological disease progression</td>
<td rowspan="1" colspan="1">0</td>
<td rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>PHYH,</em> c.135-2A&gt;G, splice site mutation (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_006214.4" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_006214.4</a>)</td>
<td rowspan="1" colspan="1">Refsum disease</td>
<td rowspan="1" colspan="1">Finsterer, J Neurol Sci (2008) [<a href="#ref029" class="usa-link" aria-describedby="ref029">29</a>]</td>
<td rowspan="1" colspan="1">Not described (Peripheral neuropathy?)</td>
<td rowspan="1" colspan="1">Case study (1)</td>
<td rowspan="1" colspan="1">Phytanic acid-poor diet (Chelsea diet)</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">Slight decrease in blood phytanic acid levels</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">Decrease in symptoms (subjective)</td>
<td rowspan="1" colspan="1">0</td>
<td rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>SCN9A,</em> c.2428 G&gt;A, p.Val810Met (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_002977.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_002977.3</a>)</td>
<td rowspan="1" colspan="1">Painful peripheral neuropathy</td>
<td rowspan="1" colspan="1">Adi, Mol Pain (2018) [<a href="#ref049" class="usa-link" aria-describedby="ref049">49</a>]</td>
<td rowspan="1" colspan="1">Distal sensory impairment, Pain insensitivity</td>
<td rowspan="1" colspan="1">Case study (1)</td>
<td rowspan="1" colspan="1">Carbamazepine</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">Use-dependent channel inhibition</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">Decrease in burning pain</td>
<td rowspan="1" colspan="1">0</td>
<td rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>SLC52A3,</em> c.639 G&gt;C, p.Tyr213Ter + c.374 C&gt;A, p.Thr125Asn (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_001370085.1" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_001370085.1</a>)</td>
<td rowspan="1" colspan="1">BVVL</td>
<td rowspan="1" colspan="1">Chaya, Semin Pediatr Neurol (2018) [<a href="#ref031" class="usa-link" aria-describedby="ref031">31</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness</td>
<td rowspan="1" colspan="1">Case study (1)</td>
<td rowspan="1" colspan="1">Riboflavin</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">Increased EGRAC &amp;riboflavin levels</td>
<td rowspan="1" colspan="1">+/=</td>
<td rowspan="1" colspan="1">Slight increase in motor function</td>
<td rowspan="1" colspan="1">0</td>
<td rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>SLC52A2,</em> c.916 G&gt;A, p.Gly306Arg (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_001253815.2" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_001253815.2</a>) +*7 other mutations</td>
<td rowspan="1" colspan="1">BVVL</td>
<td rowspan="1" colspan="1">Foley, Brain (2014) [<a href="#ref028" class="usa-link" aria-describedby="ref028">28</a>]</td>
<td rowspan="1" colspan="1">Patient I1: Muscle weakness, Functional respiratory abnormality; Patient E1: Same as I1 + Visual impairment, Hearing impairment</td>
<td rowspan="1" colspan="1">Case series (2)</td>
<td rowspan="1" colspan="1">Riboflavin</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">Decreased (normalised) acylcarnitine levels</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">Patient I1: Increased motor &amp;respiratory function in patient I1; Patient E1: Same as I1 + decreased visual &amp;hearing impairment in patient</td>
<td rowspan="1" colspan="1">1</td>
<td rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>SPTLC1,</em> N/A</td>
<td rowspan="1" colspan="1">HSAN1</td>
<td rowspan="1" colspan="1">Fridman, Neurology (2019) [<a href="#ref050" class="usa-link" aria-describedby="ref050">50</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment</td>
<td rowspan="1" colspan="1">RCT (18)</td>
<td rowspan="1" colspan="1">L-serine</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">Significant decrease in deoxysphinganine levels</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">Significant decrease in CMTNS compared with placebo</td>
<td rowspan="1" colspan="1">5</td>
<td rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>SPTLC2,</em> c.547 C&gt;T, p.Arg183Trp (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_004863.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_004863.3</a>)</td>
<td rowspan="1" colspan="1">HSAN1C</td>
<td rowspan="1" colspan="1">Auranen, Cold Spring Harb Mol Case Stud (2017) [<a href="#ref051" class="usa-link" aria-describedby="ref051">51</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment</td>
<td rowspan="1" colspan="1">Case study (1)</td>
<td rowspan="1" colspan="1">L-serine</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">Decreased deoxysphinganine levels</td>
<td rowspan="1" colspan="1">=</td>
<td rowspan="1" colspan="1">Slight increase in CMTNS score</td>
<td rowspan="1" colspan="1">0</td>
<td rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>PMP22,</em> c.215 C&gt;T, p.Ser72Leu (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000304.4" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000304.4</a>)</td>
<td rowspan="1" colspan="1">CMT3</td>
<td rowspan="1" colspan="1">Burns, Pediatr Neurol (2009) [<a href="#ref052" class="usa-link" aria-describedby="ref052">52</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Functional respiratory abnormality</td>
<td rowspan="1" colspan="1">Case study (1)</td>
<td rowspan="1" colspan="1">Curcumin</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Not described</td>
<td rowspan="1" colspan="1">=</td>
<td rowspan="1" colspan="1">No change in neurophysiology, muscle strength, respiratory function, disability or QoL</td>
<td rowspan="1" colspan="1">0</td>
<td rowspan="1" colspan="1">4</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/jnd-8-jnd200546-t003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p35"><p>Summary of results in other CMT subtypes and metabolic neuropathies. Key: HSAN3 Hereditary sensory and autonomic neuropathy type 3, CMT2 Charcot-Marie-Tooth type 2, CMT2 Charcot-Marie-Tooth type 3, MTHFR Methylenetetrahydrofolate reductase deficiency, HNPP Hereditary neuropathy with liability to pressure palsies, BVVL Brown-Violetto-Van-Laare syndrome, HSAN1 Hereditary Sensory and Autonomic Neuropathy type 1, HSAN1 C Hereditary Sensory and Autonomic Neuropathy type 1 C, DHA Docosahexaenoic acid, + positive change, - negative change, = no change, NCV nerve conduction velocity, CMAP compound muscle action potential, RCT randomised controlled trial, V50M p.Val50Met mutation, NIS-LL Neuropathy Impairment Score in the Lower Limbs, QoL Quality of Life, FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, eGFR estimated glomerular filtration rate, EGRAC erythrocyte glutathione reductase activity coefficient, mNIS+7 modified Neuropathy Impairment Score (+7 neurophysiologic tests), *Licensed for other indications.</p></div></div></section><p>Of all included studies (<em>n</em> = 34) the largest two genetic groups were amyloid neuropathy caused by mutations in the <em>TTR</em> gene (<em>n</em> = 15) and CMT1A, due to the duplication of <em>PMP22</em> (<em>n</em> = 8) and point mutation (<em>n</em> = 1) respectively. Numbers of studies were much fewer for other genotypes. Four studies looked at HSAN due to mutations in <em>ELP1</em> (<em>n</em> = 2), <em>SPTLC1</em> (<em>n</em> = 1) and <em>SPTLC2</em> (<em>n</em> = 1). Two studies examined Brown-Vialetto-Van Laere Syndrome caused by mutation in <em>SLC52A2</em> (<em>n</em> = 1) or <em>SLC52A3</em> (<em>n</em> = 1). The genes <em>MT-ATP6</em> (<em>n</em> = 1) and <em>SCN9A</em> (<em>n</em> = 1) each had 1 study. The remaining studies looked at neuropathies due to metabolic causes associated with mutations in <em>PHYH</em> (Refsum disease, <em>n</em> = 2).</p>
<section id="sec0040"><h3 class="pmc_sec_title">Randomised controlled clinical trials</h3>
<p>We identified 18 randomised controlled trials (RCTs). The most investigated treatment was oral ascorbic acid for CMT1A, with 6 independent studies. The studies varied in dose between 1.5 g and 4 g per day, for either 1 or 2 years. Most studies used the Charcot-Marie-Tooth Neuropathy Score (CMTNS) [<a href="#ref016" class="usa-link" aria-describedby="ref016">16</a>] as the primary outcome measure, with the possible addition of muscle strength, sensory or nerve conduction studies. However, none resulted in a statistically significant clinical improvement. Likewise, measurements of target effect (e.g. <em>PMP22</em> mRNA levels) showed no changes on treatment with ascorbic acid. On quality assessment, all ascorbic acid RCTs were scored at 5 according to the Jadad criteria, indicating that these were well designed and properly reported studies. Two studies investigated the use of PTX3003, a combination therapy of baclofen, naltrexone and sorbitol, to treat CMT1A. These were large phase II and III studies, both scoring 5 by Jadad criteria. The phase II study showed no change in Overall Neuropathy Limitation Scale (ONLS) [<a href="#ref016" class="usa-link" aria-describedby="ref016">16</a>] in the group treated with low doses, but a modest improvement in the highest dose group. This result prompted further investigation of the treatment in a phase III study. However, inconsistencies were found in the stability of the high dose formulations in the phase III study, which led to early termination of this arm of the study. Despite this, there was a small, significant improvement in neuropathy severity (ONLS) prior to termination. We conclude that although there is some evidence that PTX3003 is effective in CMT1A, doubts remain about the validity of the incomplete data from this study.</p>
<p>We identified 6 RCTs with four different compounds (tafamidis, diflunisal, patisiran, inotersen) which showed positive results in ATTR-familial amyloid polyneuropathy [<a href="#ref017" class="usa-link" aria-describedby="ref017">17</a>]. Two of these investigated the treatment of the common c.148 G&gt;A, p.Val50Met (previously called p.Val30Met) variant with tafamidis, a TTR stabiliser drug preventing TTR protein complex dissociation and thereby inhibiting amyloid formation [<a href="#ref018" class="usa-link" aria-describedby="ref018">18, 19</a>]. Both studies used 20 mg oral tafamidis daily for 18 months. The larger of these studies (<em>n</em> = 128) [<a href="#ref018" class="usa-link" aria-describedby="ref018">18</a>] did not show a significant improvement in the primary endpoints of Neuropathy Impairment Score in the Lower Limbs (NIS-LL) or Total Quality of life (TQOL), although some improvement was shown in neurological impairment (evidenced by reduced muscle weakness overall, specifically at the distal muscle sites). The smaller study (<em>n</em> = 63), however, did show a significant improvement in NIS-LL [<a href="#ref019" class="usa-link" aria-describedby="ref019">19</a>]. One other study in 130 patients treated over 2 years with diflunisal, a non-steroid anti-inflammatory drug which has been shown to stabilise TTR, reduced the rate of progression of neurological impairment and preserved quality of life compared to placebo [<a href="#ref020" class="usa-link" aria-describedby="ref020">20</a>].</p>
<p>The third study (APOLLO) examined the effect of patisiran, a double-stranded synthetic ribonucleic acid molecule (RNAi) that targets mutant and wild type <em>TTR</em>, after 18 months treatment in patients carrying the c.148 G&gt;A (p.Val50Met) (∼50% of patients) or other <em>TTR</em> mutations [<a href="#ref021" class="usa-link" aria-describedby="ref021">21, 22</a>]. There was an improvement detected by the modified Neuropathy Impairment Score (mNIS+7).</p>
<p>Inotersen, a single-stranded deoxynucleotide analogue (DNA) complementary to <em>TTR</em> pre-mRNA has also been implemented to silence <em>TTR</em> in a 15-month multi-centre RCT (NEURO-TTR) in 172 patients with <em>TTR</em>-related peripheral neuropathy, of which approximately 50% had the p.Val50Met mutation [<a href="#ref023" class="usa-link" aria-describedby="ref023">23</a>]. This trial met both of its primary endpoints, as there was significantly less decline in the neuropathy and quality of life measures in the inotersen group compared with the placebo group.</p>
<p>Two studies looked at treatment options in hereditary sensory and autonomic neuropathies (HSAN). Treatment with L-serine in 18 patients with <em>SPTLC1</em> variants resulted in significant decrease in CMTNS scores compared to placebo. Additionally, there was a corresponding decrease in deoxysphinganine levels, confirming target effect.</p></section><section id="sec0045"><h3 class="pmc_sec_title">Non-randomised trials</h3>
<p>We identified 5 non-randomised trials, all of which were open-label extensions of RCTs in patients with TTR-related neuropathy treated with patisiran, tafamidis and revusiran. These resulted in useful data on the long-term impact of these treatments. The APOLLO phase II trial showed a significant improvement in neuropathy in p.Val50Met patients following treatment with patisiran for 24 months [<a href="#ref024" class="usa-link" aria-describedby="ref024">24</a>], and formed the basis for the APOLLO phase III RCT, which gives better evidence of the efficacy of patisiran. Another trial (Pfizer) investigated the use of tafamidis in the non-p.Val50Met subpopulation of patients and demonstrated TTR stabilisation, but it did not investigate changes in the neuropathy phenotype [<a href="#ref025" class="usa-link" aria-describedby="ref025">25</a>]. Revusiran treatment (Alnylam Pharmceuticals) was administered in patients who had previously received liver transplants, but the study was terminated due to increased mortality rate in the treated patients [<a href="#ref026" class="usa-link" aria-describedby="ref026">26</a>], similar to another study in TTR-related cardiomyopathy [<a href="#ref027" class="usa-link" aria-describedby="ref027">27</a>]. The increased mortality was unlikely to be related to the treatment, but rather the effect of studying an older and more severely affected patient population.</p></section><section id="sec0050"><h3 class="pmc_sec_title">Case series</h3>
<section class="tw xbox font-sm" id="jnd-8-jnd200546-t002"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Summary of results in Transthyretin Familial amyloid polyneuropathy (TTR-FAP)</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="justify" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
</colgroup>
<thead valign="top">
<tr>
<td rowspan="1" colspan="1">Gene, Mutation</td>
<td rowspan="1" colspan="1">Title</td>
<td rowspan="1" colspan="1">First Author,</td>
<td rowspan="1" colspan="1">Phenotype</td>
<td rowspan="1" colspan="1">Study</td>
<td rowspan="1" colspan="1">Number</td>
<td rowspan="1" colspan="1">Drug</td>
<td rowspan="1" colspan="1">Duration</td>
<td colspan="2" align="center" rowspan="1">Target effect</td>
<td colspan="2" align="center" rowspan="1">Clinical effect</td>
<td rowspan="1" colspan="1">JADAD</td>
<td rowspan="1" colspan="1">OCEBM</td>
<td rowspan="1" colspan="1">UK</td>
</tr>
<tr>
<td rowspan="1" colspan="1">(RefSeq) (*see</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Journal</td>
<td rowspan="1" colspan="1">target HPO</td>
<td rowspan="1" colspan="1">type</td>
<td rowspan="1" colspan="1">of</td>
<td rowspan="1" colspan="1">name</td>
<td rowspan="1" colspan="1"></td>
<td colspan="2" align="center" rowspan="1">(+/– / =) &amp;</td>
<td colspan="2" align="center" rowspan="1">(+/– / =) &amp;</td>
<td rowspan="1" colspan="1">score</td>
<td rowspan="1" colspan="1">score</td>
<td rowspan="1" colspan="1">License</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<a href="#S1" class="usa-link">Supplement 3</a>
</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">(Year)</td>
<td rowspan="1" colspan="1">term(s)</td>
<td rowspan="1" colspan="1">Patients</td>
<td colspan="2" align="center" rowspan="1">description</td>
<td colspan="2" align="center" rowspan="1">description</td>
<td rowspan="1" colspan="1">(1– 5)</td>
<td rowspan="1" colspan="1">(1– 5)</td>
<td rowspan="1" colspan="1">(Y/N)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">for other</td>
<td colspan="2" align="center" rowspan="1"></td>
<td colspan="2" align="center" rowspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">mutations)</td>
<td colspan="2" align="center" rowspan="1"></td>
<td colspan="2" align="center" rowspan="1"></td>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">
<em>TTR,</em> c.148 G&gt;A, p.Val50Met (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000371.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000371.3</a>) +*21 other mutations</td>
<td rowspan="1" colspan="1">Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial</td>
<td rowspan="1" colspan="1">Berk, JAMA (2013) [<a href="#ref020" class="usa-link" aria-describedby="ref020">20</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment</td>
<td rowspan="1" colspan="1">RCT</td>
<td rowspan="1" colspan="1">130 (71 V30M, 59 other mutations)</td>
<td rowspan="1" colspan="1">Diflunisal</td>
<td rowspan="1" colspan="1">2 years</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Not described</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">↑NIS+7, ↓Progression of neuropathy, ↑QoL (↓SF-36 physical, ↑SF-36 mental)</td>
<td rowspan="1" colspan="1">1</td>
<td rowspan="1" colspan="1">2</td>
<td rowspan="1" colspan="1">*N</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>TTR,</em> c.148 G&gt;A, p.Val50Met (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000371.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000371.3</a>)</td>
<td rowspan="1" colspan="1">Tafamidis for Transthyretin Familial Amyloid Polyneuropathy: A Randomized, Controlled Trial</td>
<td rowspan="1" colspan="1">Coelho, Neurology (2012) [<a href="#ref018" class="usa-link" aria-describedby="ref018">18</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, sensory impairment</td>
<td rowspan="1" colspan="1">RCT</td>
<td rowspan="1" colspan="1">128</td>
<td rowspan="1" colspan="1">Tafamidis</td>
<td rowspan="1" colspan="1">18 months</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">TTR stabilisation</td>
<td rowspan="1" colspan="1">=/+</td>
<td rowspan="1" colspan="1">No change in NIS-LL or total QoL, ↓progression neuropathy</td>
<td rowspan="1" colspan="1">5</td>
<td rowspan="1" colspan="1">2</td>
<td rowspan="1" colspan="1">Y</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>TTR,</em> c.148 G&gt;A, p.Val50Met (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000371.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000371.3</a>) +*8 other mutations</td>
<td rowspan="1" colspan="1">Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years</td>
<td rowspan="1" colspan="1">Barroso, Amyloid (2017) [<a href="#ref041" class="usa-link" aria-describedby="ref041">41</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment</td>
<td rowspan="1" colspan="1">Open label extension study</td>
<td rowspan="1" colspan="1">93 (75 V30M + 18 non-V30M)</td>
<td rowspan="1" colspan="1">Tafamidis</td>
<td rowspan="1" colspan="1">6 years</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Not described</td>
<td rowspan="1" colspan="1">=/+</td>
<td rowspan="1" colspan="1">Significant delay neuropathy progression</td>
<td rowspan="1" colspan="1">1</td>
<td rowspan="1" colspan="1">3</td>
<td rowspan="1" colspan="1">Y</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>TTR,</em> c.224T&gt;C, p.Leu75Pro (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000371.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000371.3</a>)</td>
<td rowspan="1" colspan="1">Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report</td>
<td rowspan="1" colspan="1">Kon, Amyloid (2015) [<a href="#ref042" class="usa-link" aria-describedby="ref042">42</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment, Cardiomyopathy</td>
<td rowspan="1" colspan="1">Case study</td>
<td rowspan="1" colspan="1">1</td>
<td rowspan="1" colspan="1">Tafamidis</td>
<td rowspan="1" colspan="1">1 year</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Not described</td>
<td rowspan="1" colspan="1">=/+</td>
<td rowspan="1" colspan="1">↓Progression of polyneuropathy &amp;cardiac amyloidosis</td>
<td rowspan="1" colspan="1">0</td>
<td rowspan="1" colspan="1">4</td>
<td rowspan="1" colspan="1">Y</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>TTR,</em> c.148 G&gt;A, p.Val30Met (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000371.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000371.3</a>) +*8 other mutations</td>
<td rowspan="1" colspan="1">Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area</td>
<td rowspan="1" colspan="1">Cortese, J Neurol (2016) [<a href="#ref043" class="usa-link" aria-describedby="ref043">43</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment, Cardiomyopathy</td>
<td rowspan="1" colspan="1">Cohort study</td>
<td rowspan="1" colspan="1">61</td>
<td rowspan="1" colspan="1">Tafamidis</td>
<td rowspan="1" colspan="1">3 years</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Not described</td>
<td rowspan="1" colspan="1">=/+</td>
<td rowspan="1" colspan="1">No effect in V30M, ↓neuropathy progression in non-V30M &amp;high disability</td>
<td rowspan="1" colspan="1">1</td>
<td rowspan="1" colspan="1">3</td>
<td rowspan="1" colspan="1">Y</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>TTR,</em> c.173A&gt;C, p.Asp58Ala (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000371.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000371.3</a>)</td>
<td rowspan="1" colspan="1">Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report</td>
<td rowspan="1" colspan="1">Fujita, Cardiology (2017) [<a href="#ref044" class="usa-link" aria-describedby="ref044">44</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment, Cardiomyopathy</td>
<td rowspan="1" colspan="1">Case study</td>
<td rowspan="1" colspan="1">1</td>
<td rowspan="1" colspan="1">Tafamidis meglumine</td>
<td rowspan="1" colspan="1">2 years</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Not described</td>
<td rowspan="1" colspan="1">=/–</td>
<td rowspan="1" colspan="1">No change in nerve conduction (axonopathy), progression of amyloid cardiomyopathy</td>
<td rowspan="1" colspan="1">0</td>
<td rowspan="1" colspan="1">4</td>
<td rowspan="1" colspan="1">Y</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>TTR,</em> c.290 C&gt;A, p.Ser97Tyr (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000371.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000371.3</a>) + *13 other mutations</td>
<td rowspan="1" colspan="1">The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients with Non-V30M Transthyretin Amyloidosis</td>
<td rowspan="1" colspan="1">EudraCT number: 2007-006791-12 (2016) [<a href="#ref025" class="usa-link" aria-describedby="ref025">25</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment, Cardiomyopathy</td>
<td rowspan="1" colspan="1">Open label study</td>
<td rowspan="1" colspan="1">21</td>
<td rowspan="1" colspan="1">Tafamidis</td>
<td rowspan="1" colspan="1">43– 76 years</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">TTR stabilisation</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">N/A</td>
<td rowspan="1" colspan="1">1</td>
<td rowspan="1" colspan="1">3</td>
<td rowspan="1" colspan="1">*N</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>TTR,</em> c.401A&gt;G, p.Tyr134Cys (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000371.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000371.3</a>)</td>
<td rowspan="1" colspan="1">Transthyretin-related hereditary amyloidosis in an Argentinian family with TTR Tyr114Cys mutation</td>
<td rowspan="1" colspan="1">M. A. Aguirre, Amyloid (2017) [<a href="#ref045" class="usa-link" aria-describedby="ref045">45</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment, Cardiomyopathy</td>
<td rowspan="1" colspan="1">Case study</td>
<td rowspan="1" colspan="1">1</td>
<td rowspan="1" colspan="1">Tafamidis</td>
<td rowspan="1" colspan="1">65 years</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Not described</td>
<td rowspan="1" colspan="1">N/A</td>
<td rowspan="1" colspan="1">Discontinued due to adverse effects</td>
<td rowspan="1" colspan="1">0</td>
<td rowspan="1" colspan="1">4</td>
<td rowspan="1" colspan="1">Y</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>TTR,</em> c.148 G&gt;A, p.Val30Met (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000371.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000371.3</a>)</td>
<td rowspan="1" colspan="1">Safety and Efficacy of Orally Administered Fx-1006A in Patients with Familial Amyloid Polyneuropathy (FAP): a Phase II/III, Randomised, Double-Blind, Placebo-Controlled Study</td>
<td rowspan="1" colspan="1">EudraCT number: 2006-002792-41 (2009) [<a href="#ref019" class="usa-link" aria-describedby="ref019">19</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment, Cardiomyopathy</td>
<td rowspan="1" colspan="1">RCT</td>
<td rowspan="1" colspan="1">63</td>
<td rowspan="1" colspan="1">Tafamidis</td>
<td rowspan="1" colspan="1">25– 74 years</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Not described</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">↓change from baseline NSLL LSMean score</td>
<td rowspan="1" colspan="1">3</td>
<td rowspan="1" colspan="1">2</td>
<td rowspan="1" colspan="1">Y</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>TTR</em> (V30M and others)</td>
<td rowspan="1" colspan="1">The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin</td>
<td rowspan="1" colspan="1">Clinicaltrials.gov Identifier: <a href="https://clinicaltrials.gov/ct2/show/NCT01435655" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01435655</a> (2015)</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment, Cardiomyopathy</td>
<td rowspan="1" colspan="1">RCT</td>
<td rowspan="1" colspan="1">10</td>
<td rowspan="1" colspan="1">Tafamidis</td>
<td rowspan="1" colspan="1">20– 75 years</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Not described</td>
<td rowspan="1" colspan="1">=</td>
<td rowspan="1" colspan="1">No observable change in clinical outcomes</td>
<td rowspan="1" colspan="1">0</td>
<td rowspan="1" colspan="1">4</td>
<td rowspan="1" colspan="1">Y</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>TTR,</em> c.148 G&gt;A, p.Val30Met (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000371.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000371.3</a>) + *38 other mutations</td>
<td rowspan="1" colspan="1">APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP) + Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis</td>
<td rowspan="1" colspan="1">EudraCT number: 2013-002987-17 (2017) [<a href="#ref022" class="usa-link" aria-describedby="ref022">22</a>] Adams, Neurology (2018) [<a href="#ref021" class="usa-link" aria-describedby="ref021">21</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment, Cardiomyopathy</td>
<td rowspan="1" colspan="1">RCT</td>
<td rowspan="1" colspan="1">77</td>
<td rowspan="1" colspan="1">Patisiran</td>
<td rowspan="1" colspan="1">24– 83 years</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">↓serum TTR</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">↓change from baseline in mNIS+7 neuropathy score, ↓change from baseline in Norfolk QOL-DN score</td>
<td rowspan="1" colspan="1">5</td>
<td rowspan="1" colspan="1">2</td>
<td rowspan="1" colspan="1">Y</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>TTR</em> (Not described)</td>
<td rowspan="1" colspan="1">A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02</td>
<td rowspan="1" colspan="1">EudraCT number: 2013-001644-65 (2017) [<a href="#ref024" class="usa-link" aria-describedby="ref024">24</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment, Cardiomyopathy</td>
<td rowspan="1" colspan="1">RCT</td>
<td rowspan="1" colspan="1">27</td>
<td rowspan="1" colspan="1">Patisiran</td>
<td rowspan="1" colspan="1">18– 84 years</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">92% decrease in serum TTR</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">Significant improvement in neuropathy</td>
<td rowspan="1" colspan="1">1</td>
<td rowspan="1" colspan="1">3</td>
<td rowspan="1" colspan="1">Y</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>TTR</em> (Not described)</td>
<td rowspan="1" colspan="1">An Open-Label Study To Evaluate The Efficacy And Safety Of Revusiran In Patients With Transthyretin-Mediated Familial Amyloidotic Polyneuropathy With Disease Progression Post Orthotopic Liver Transplant</td>
<td rowspan="1" colspan="1">EudraCT number: 2015-002603-29 (2018) [<a href="#ref026" class="usa-link" aria-describedby="ref026">26</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment, Cardiomyopathy</td>
<td rowspan="1" colspan="1">RCT</td>
<td rowspan="1" colspan="1">12</td>
<td rowspan="1" colspan="1">Revusiran</td>
<td rowspan="1" colspan="1">18– 84 years</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Not described</td>
<td rowspan="1" colspan="1">N/A</td>
<td rowspan="1" colspan="1">Study terminated</td>
<td rowspan="1" colspan="1">1</td>
<td rowspan="1" colspan="1">3</td>
<td rowspan="1" colspan="1">N</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>TTR,</em> c.148 G&gt;A, p.Val30Met (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000371.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000371.3</a>) + *26 other mutations</td>
<td rowspan="1" colspan="1">Inotersen Treatment for Patients With Hereditary Transthyretin Amyloidosis</td>
<td rowspan="1" colspan="1">M. D. Benson, N Engl J Med (2018) [<a href="#ref023" class="usa-link" aria-describedby="ref023">23</a>]</td>
<td rowspan="1" colspan="1">Muscle weakness, Distal sensory impairment, Cardiomyopathy</td>
<td rowspan="1" colspan="1">RCT</td>
<td rowspan="1" colspan="1">172</td>
<td rowspan="1" colspan="1">Inotersen</td>
<td rowspan="1" colspan="1">18– 83 years</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">↓serum TTR</td>
<td rowspan="1" colspan="1">+</td>
<td rowspan="1" colspan="1">↓change from baseline in mNIS+7 neuropathy score, ↓change from baseline Norfolk QOL-DN score</td>
<td rowspan="1" colspan="1">5</td>
<td rowspan="1" colspan="1">2</td>
<td rowspan="1" colspan="1">Y</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/jnd-8-jnd200546-t002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p30"><p>Summary of results in Transthyretin Familial amyloid polyneuropathy (TTR-FAP). Key: + positive change, - negative change, = no change, NCV nerve conduction velocity, RCT randomised controlled trial, V30M p.Val30Met mutation, NIS-LL Neuropathy Impairment Score in the Lower Limbs, QoL Quality of Life, mNIS+7 modified Neuropathy Impairment Score (+7 neurophysiologic tests), SF-36 Short Form 36 Health Survey Questionnaire. (*licensed for other indications).</p></div></div></section><p>Fourteen case studies or case series were identified, all of which included only a few or single patients. These represented incidental findings on patients with unusual presentations or reported on treatments already established to be effective in larger studies (<a href="#jnd-8-jnd200546-t001" class="usa-link">Tables 1</a>–<a href="#jnd-8-jnd200546-t001" class="usa-link">3</a>). However, there were several interesting examples of seemingly effective genotype-specific targeted treatments of the molecular defect, which should be considered in patients with causative mutations in these genes. One case study highlighted a positive effect of riboflavin in a single patient with Brown-Vialetto-Van-Laere syndrome (BVVL) due to mutations in the riboflavin transporter (<em>SLC52A2/3)</em>. Another study investigating riboflavin treatment for BVVL, not identified in literature but known to R.H., was also included [<a href="#ref028" class="usa-link" aria-describedby="ref028">28</a>]. This publication was not detected in our original search as it did not include search terms ‘genetic’ or ‘inherited’ in the title or abstract. High dose riboflavin was shown to have a positive effect on neurological symptoms in both <em>SLC52A2</em> and <em>SLC52A3</em> genotypes, and early treatment of these patients may prevent neurological deterioration [<a href="#ref028" class="usa-link" aria-describedby="ref028">28</a>].</p>
<p>Other targeted treatments with positive results include low phytanic acid diet in Refsum disease, an inborn error of metabolism in which high phytanic acid results in neurological symptoms [<a href="#ref029" class="usa-link" aria-describedby="ref029">29, 30</a>], and a case study with L-serine in a patient with HSAN due to <em>SPTLC2</em> mutation decreased deoxysphinganine levels [<a href="#ref031" class="usa-link" aria-describedby="ref031">31</a>].</p>
<p>Several case studies were not included in <a href="#jnd-8-jnd200546-t001" class="usa-link">Tables 1</a>-3 due to case-specific reasons given below, as decided by the expert team lead (R.H.). Four case studies investigating immune therapies were excluded, as they were thought to be treating secondary immune-mediated neuropathies rather than the primary hereditary neuropathy and were therefore not gene specific. Furthermore, these treatments may even be harmful in hereditary neuropathies. Another case study of potential benefit was reported in a patient with neuropathy caused by docosahexaenoic acid (DHA) deficiency, which was treated with cod liver oil (high levels of DHA), however the causative mutation was not identified [<a href="#ref032" class="usa-link" aria-describedby="ref032">32</a>]. Four other studies were excluded on the basis of treating non-gene specific symptoms of neuropathies, such as foot deformity in CMT1A and CMT4A, erectile dysfunction in TTR and fatigue in CMT1A. One uncontrolled trial investigating algasidase alfa in Fabry disease and another study on treatment with betain, folinic acid, B12 and B6 vitamins to restore the folate pathway in <em>MTHFR</em> mutations were excluded because these are complex diseases and cannot be listed as a specific neuropathy treatment.</p></section><section id="sec0055"><h3 class="pmc_sec_title">Distribution and relationships of Jadad and OCEBM scores</h3>
<p>Both Jadad and OCEBM scores aim to give an estimate of the scientific credit of a study, illustrated by a very high degree of correlation between the two scores (<a href="#jnd-8-jnd200546-g003" class="usa-link">Fig. 3B</a>), with 34/47 studies belonging to 2 clusters of studies. Studies with low OCEBM (≤2) and high Jadad (5) are well conducted RCTs, while studies with high OCEBM (4) and low Jadad (0) represent case studies or case series lacking most of the desired features of a good clinical trial.</p>
<figure class="fig xbox font-sm" id="jnd-8-jnd200546-g003"><h4 class="obj_head">Fig.3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8203235_jnd-8-jnd200546-g003.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f113/8203235/d6f2d22f8d51/jnd-8-jnd200546-g003.jpg" loading="lazy" height="704" width="725" alt="Fig.3"></a></p>
<div class="p text-right font-secondary"><a href="figure/jnd-8-jnd200546-g003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Meta-analysis of studies. (A) Comparison of OCEBM levels with Jadad scoring, the size of each point indicating the number of studies at that point, colour indicating the quality defined as the product of these two scores (lower OCEBM with higher Jadad being the highest quality studies). (B) Distribution of study outcomes, stratified by patient number and labelled by study type.</p></figcaption></figure></section></section><section id="sec0060"><h2 class="pmc_sec_title">DISCUSSION</h2>
<p>We performed a systematic review to evaluate the evidence for pharmacological and gene-based treatments in inherited peripheral neuropathies. Our original search identified 1892 independent publications, of which 34 were included in our final analysis. The evidence for the efficacy of the studied treatments was weighted based on the quality of the clinical trials or case studies. We identified 15 treatments, which should be initiated in patients with some genetic forms of inherited neuropathies.</p>
<p>However, our study has some limitations. Firstly, we may have missed some papers reporting positive effect of a treatment as part of a larger study on novel disease genes or describing large cohorts of diverse patients. However, search terms including these would have produced many times more results, thereby precluding careful consideration of studies. The future inclusion of machine-readable variant-level genotype information in clinical trial registration and reporting would improve data collation in the rare disease field. Indeed, we had to add one paper based on our expertise in inherited neuropathies on riboflavin-responsive neuropathy (BVVL) [<a href="#ref028" class="usa-link" aria-describedby="ref028">28, 31</a>]. Secondly, although there are supporting data on the rationale and efficacy of some of these treatments, the degree of evidence is not satisfactory in many studies. The reasons include insufficient study design, inappropriate outcome measures, low number of participants and short study duration. Our review highlights these limitations and demonstrates that we must improve our standards in planning clinical trials. Careful consideration of study size and duration, number of participants, appropriate outcome measures and international collaboration (multi-centre studies) are essential to improve the development of treatments in inherited neuropathies. Thirdly, many studies did not give gene and variant data of study participants in sufficient detail, which meant they were of limited use to our study. Lastly, this database needs regular updating in the future, as the number of clinical trials and relevant case studies are steadily increasing in inherited peripheral neuropathies. This is a time intensive process and requires a dedicated expert team.</p>
<p>Most evidence has been gathered in CMT1A. Ascorbic acid has been extensively researched and proven to be ineffective in this disease subtype. More recently, a combination of baclofen, naltrexone and sorbitol (PXT3003) has shown significant improvement in CMT scores (CMTNS and ONLS) and may be a strong candidate for pharmacotherapy in the future. However, these results must first be confirmed in the phase III trial currently ongoing [<a href="#ref001" class="usa-link" aria-describedby="ref001">1</a>]. Therefore, based on the evidence presented in this review, no definitive recommendations can be made for first-line treatment at present.</p>
<p>In <em>TTR</em>-related amyloid neuropathy, four treatments (tafamidis, patisiran, inotersen and diflunisal) showed significant benefit in high quality RCTs and should be initiated in patients with pathogenic variants in <em>TTR</em>. These drugs have been approved in many different countries for treatment of <em>TTR</em>-related neuropathy. There are still uncertainties about what the long-term clinical benefits are, when to initiate treatment and how to incorporate these treatments into the current algorithms. The choice of treatment and time of commencement needs careful consideration in specialised centres [<a href="#ref017" class="usa-link" aria-describedby="ref017">17</a>], and is influenced by national regulatory and licensing guidelines [<a href="#ref033" class="usa-link" aria-describedby="ref033">33</a>]. Early diagnosis of this condition is essential for timely access to treatment. The availability of gene silencing treatments raises issues regarding genetic screening and management of asymptomatic individuals.</p>
<p>In other forms of CMT and metabolic neuropathies, treatment recommendations are based on a slightly weaker evidence base of case studies and smaller trials. A positive effect of L-serine supplementation in patients with HSAN due to mutations in <em>SPTLC1</em> (and potentially SPTLC2) is emerging, and we highlighted the efficacy of targeted dietary supplementation and restriction in a few other rare genetic neuropathies (BVVL, Refsum and methylenetetrahydrofolate reductase deficiency). Therefore, if pathogenic mutations are identified in these genes, targeted treatments should be considered in clinical practice.</p>
<p>We detected an increase in the number of publications in recent years (<a href="#jnd-8-jnd200546-g002" class="usa-link">Fig. 2B</a>), although this increase was still driven mainly by case studies and case series. Well-designed RCTs were performed mostly in CMT1A and in amyloid neuropathy caused by <em>TTR</em> mutations (<a href="#jnd-8-jnd200546-g002" class="usa-link">Fig. 2B</a>). When plotting study size against clinical outcome (<a href="#jnd-8-jnd200546-g003" class="usa-link">Fig. 3B</a>), we observed that RCTs with the largest patient enrolments (<em>n</em> &gt; 100) were more likely to demonstrate efficacy in <em>TTR</em> amyloid neuropathy or conclude lack of benefit in CMT1A. This reflects the greater statistical power of larger studies as compared to smaller studies. Case studies and small case series are more likely to report a clinical improvement, but this may be based on unsatisfactory evidence. For example, there is often reporting bias as unusual patient presentations are more likely to be reported. However, some case studies targeting the molecular defect in rare metabolic conditions should be applied to treat specific genetic neuropathies even without performing RCTs.</p>
<figure class="fig xbox font-sm" id="jnd-8-jnd200546-g002"><h3 class="obj_head">Fig.2.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8203235_jnd-8-jnd200546-g002.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f113/8203235/6aed72fee449/jnd-8-jnd200546-g002.jpg" loading="lazy" height="755" width="753" alt="Fig.2"></a></p>
<div class="p text-right font-secondary"><a href="figure/jnd-8-jnd200546-g002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Characteristics of included studies. (A) Treemap showing number of studies by mutated gene. (B) Percentages of study type for studies overall, and then broken down by disease type (amyloid TTR neuropathy, ATTR; Charcot-Marie-Tooth type 1A, CMT1A; all other studies). (C) Distribution of publications by year, colours indicating study types.</p></figcaption></figure><p>Although the number of effective treatments in inherited peripheral neuropathies is still very limited, the availability of large international patient cohorts, better outcome measures and more accurate natural history data will facilitate the development of further effective therapies. The recent identification of new genetic forms of CMT has launched research into developing novel therapies, which may in the future be added to the treatabolome database. Since the completion of our search, the discovery of mutations in <em>SORD</em> has unveiled how existing aldose reductase inhibitors have great potential to treat this common type of CMT [<a href="#ref034" class="usa-link" aria-describedby="ref034">34</a>]. Based on <em>in vitro</em> studies in patient-derived fibroblasts and in Drosophila, aldose reductase inhibitors normalized intracellular sorbitol levels and also ameliorated motor and eye phenotypes. These findings will form the basis for future clinical trials in patients with this form of CMT. Further progress is being made due to the technological advancements in molecular genetics, allowing scientists to generate diverse animal models that closely resemble the CMT phenotype. Additionally, it is now possible to culture patient-derived neurons in a dish using cellular reprogramming and differentiation techniques [<a href="#ref035" class="usa-link" aria-describedby="ref035">35</a>].</p>
<p>There is an ever-increasing need for data sharing in rare genetic diseases. This need is beginning to be met by the establishment and implementation of several large databases, which integrate next generation sequencing data with clinical phenotyping data (e.g. RD-CONNECT, DECIPHER, GENESIS, etc). These databases contain information on several thousands of patients and their family members, as well as being easily accessible to clinicians analysing their patients’ samples. On average, each human genome has approximately 30,000 variants compared to the standard assembly, which may be benign or pathogenic. For this reason, appropriate filtering for rare, causative variants and linking the available phenotypic information (HPO terms in RD-CONNECT) results in a higher diagnostic rate. Furthermore, to enable rapid translation from diagnosis to treatment, variants in the genes highlighted as part of the treatabolome project will be flagged in RD-CONNECT. This data will be immediately reported back to the clinician, together with the genetic diagnosis as determined by exome sequencing. Our work will allow this streamlined solution to be made available to clinicians dealing with inherited peripheral neuropathy patients. This approach facilitates clinicians’ access to the latest clinical data relevant to the genotype of their patients and enables timely treatment, ultimately leading to improved prognosis and a better quality of life of rare disease patients. The treatabolome project therefore offers a powerful tool, with significant advantages for both clinicians and patients with inherited peripheral neuropathies.</p></section><section id="sec0065"><h2 class="pmc_sec_title">Funding</h2>
<p>The authors of this study are supported by the Newton Fund UK/Turkey (MR/N027302/1 to RH), the Medical Research Council (UK) (MR/N025431/1 to RH), the Wellcome Investigator fund (109915/Z/15/Z to RH), the Lily Foundation UK (to RH), the European Research Council (309548 to RH) and the Evelyn Trust (19/14 to RH); and the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z to RH). The study was further supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD”, the RD-Connect Genome-Phenome Analysis platform developed under FP7/2007-2013 funded project (grant agreement nº 305444).). Authors of this publication are members of the European Reference Network for Rare Neuromuscular Diseases EURO-NMD (AA, RH).</p></section><section id="sec19"><h2 class="pmc_sec_title">Supplementary Material</h2>
<section class="sm xbox font-sm" id="S1"><div class="caption p"><span>Supplementary Tables 1 and 3</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/8203235/bin/jnd-8-jnd200546-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">Click here for additional data file.</a><sup> (35.7KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="S2"><div class="caption p"><span>Supplementary Table 2</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/8203235/bin/jnd-8-jnd200546-s002.csv" data-ga-action="click_feat_suppl" class="usa-link">Click here for additional data file.</a><sup> (23.9KB, csv) </sup>
</div></div></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">SUPPLEMENTARY MATERIAL</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn2"><p>The supplementary material is available in the electronic version of this article: <a href="http://dx.doi.org/10.3233/JND-200546" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://dx.doi.org/10.3233/JND-200546</a>.</p></div></div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">REFERENCES</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="ref001">
<span class="label">[1].</span><cite>Dawkins HJS, et al. Progress in Rare Diseases Research 2010-2016: An IRDiRC Perspective. Clin Transl Sci. 2018;11(1):11–20.</cite> [<a href="https://doi.org/10.1111/cts.12501" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5759730/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28796411/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Transl%20Sci&amp;title=Progress%20in%20Rare%20Diseases%20Research%202010-2016:%20An%20IRDiRC%20Perspective&amp;author=HJS%20Dawkins&amp;volume=11&amp;issue=1&amp;publication_year=2018&amp;pages=11-20&amp;pmid=28796411&amp;doi=10.1111/cts.12501&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref002">
<span class="label">[2].</span><cite>Nguengang Wakap S, Lambert DM. Estimating cumulative point prevalence of rare diseases: Analysis of the Orphanet database (2020;28(2):165–73.</cite> [<a href="https://doi.org/10.1038/s41431-019-0508-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6974615/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31527858/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nguengang%20Wakap%20S,%20Lambert%20DM.%20Estimating%20cumulative%20point%20prevalence%20of%20rare%20diseases:%20Analysis%20of%20the%20Orphanet%20database%20(2020;28(2):165%E2%80%9373." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref003">
<span class="label">[3].</span><cite>Thompson R, et al. Targeted therapies for congenital myasthenic syndromes: Systematic review and steps towards a treatabolome. Emerging Topics in Life Sciences. 2019;3(1):19–37.</cite> [<a href="https://doi.org/10.1042/ETLS20180100" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6436731/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30931400/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Emerging%20Topics%20in%20Life%20Sciences&amp;title=Targeted%20therapies%20for%20congenital%20myasthenic%20syndromes:%20Systematic%20review%20and%20steps%20towards%20a%20treatabolome&amp;author=R%20Thompson&amp;volume=3&amp;issue=1&amp;publication_year=2019&amp;pages=19-37&amp;pmid=30931400&amp;doi=10.1042/ETLS20180100&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref004">
<span class="label">[4].</span><cite>Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth’s disease. Clin Genet. 1974;6(2):98–118.</cite> [<a href="https://doi.org/10.1111/j.1399-0004.1974.tb00638.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/4430158/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Genet&amp;title=Genetic%20and%20clinical%20aspects%20of%20Charcot-Marie-Tooth%E2%80%99s%20disease&amp;author=H%20Skre&amp;volume=6&amp;issue=2&amp;publication_year=1974&amp;pages=98-118&amp;pmid=4430158&amp;doi=10.1111/j.1399-0004.1974.tb00638.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref005">
<span class="label">[5].</span><cite>Bansagi B, et al. Genetic heterogeneity of motor neuropathies. Neurology. 2017;88(13):1226–34.</cite> [<a href="https://doi.org/10.1212/WNL.0000000000003772" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5373778/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28251916/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Genetic%20heterogeneity%20of%20motor%20neuropathies&amp;author=B%20Bansagi&amp;volume=88&amp;issue=13&amp;publication_year=2017&amp;pages=1226-34&amp;pmid=28251916&amp;doi=10.1212/WNL.0000000000003772&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref006">
<span class="label">[6].</span><cite>Benarroch L, et al. The 2020 version of the gene table of neuromuscular disorders (nuclear genome). Neuromuscul Disord. 2019;29(12):980–1018.</cite> [<a href="https://doi.org/10.1016/j.nmd.2019.10.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31791870/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neuromuscul%20Disord&amp;title=The%202020%20version%20of%20the%20gene%20table%20of%20neuromuscular%20disorders%20(nuclear%20genome)&amp;author=L%20Benarroch&amp;volume=29&amp;issue=12&amp;publication_year=2019&amp;pages=980-1018&amp;pmid=31791870&amp;doi=10.1016/j.nmd.2019.10.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref007">
<span class="label">[7].</span><cite>Reilly MM, Murphy SM, Laura M. Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2011;16(1):1–14.</cite> [<a href="https://doi.org/10.1111/j.1529-8027.2011.00324.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21504497/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Peripher%20Nerv%20Syst&amp;title=Charcot-Marie-Tooth%20disease&amp;author=MM%20Reilly&amp;author=SM%20Murphy&amp;author=M%20Laura&amp;volume=16&amp;issue=1&amp;publication_year=2011&amp;pages=1-14&amp;pmid=21504497&amp;doi=10.1111/j.1529-8027.2011.00324.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref008">
<span class="label">[8].</span><cite>Bis-Brewer DM, Fazal S, Zuchner S. Genetic modifiers and non-Mendelian aspects of CMT. Brain Res. 1726)146459.</cite> [<a href="https://doi.org/10.1016/j.brainres.2019.146459" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6925904/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31525351/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Brain%20Res&amp;title=Genetic%20modifiers%20and%20non-Mendelian%20aspects%20of%20CMT&amp;author=DM%20Bis-Brewer&amp;author=S%20Fazal&amp;author=S%20Zuchner&amp;publication_year=1726&amp;pages=146459&amp;pmid=31525351&amp;doi=10.1016/j.brainres.2019.146459&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref009">
<span class="label">[9].</span><cite>McCorquodale D, Pucillo EM, Johnson NE. Management of Charcot-Marie-Tooth disease: Improving long-term care with a multidisciplinary approach. J Multidiscip Healthc. 2016;9:7–19.</cite> [<a href="https://doi.org/10.2147/JMDH.S69979" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4725690/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26855581/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Multidiscip%20Healthc&amp;title=Management%20of%20Charcot-Marie-Tooth%20disease:%20Improving%20long-term%20care%20with%20a%20multidisciplinary%20approach&amp;author=D%20McCorquodale&amp;author=EM%20Pucillo&amp;author=NE%20Johnson&amp;volume=9&amp;publication_year=2016&amp;pages=7-19&amp;pmid=26855581&amp;doi=10.2147/JMDH.S69979&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref010">
<span class="label">[10].</span><cite>Higgins J J.P.T.T.J.C.J.C.M.L.T.P.M.J.W.V.A. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane, version 6.0 (updated July 2019) availible from. <a href="http://www.training.cochrane.og/handbook" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">www.training.cochrane.og/handbook</a>.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Cochrane,%20version%206.0%20(updated%20July%202019)%20availible%20from&amp;title=Cochrane%20Handbook%20for%20Systematic%20Reviews%20of%20Interventions&amp;author=J.P.T.T.J.C.J.C.M.L.T.P.M.J.W.V.A%20Higgins%20J&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref011">
<span class="label">[11].</span><cite>
Group, O.L.o.E.W. The Oxford Levels of Evidence 2 2011 [cited 2019; Available from: <a href="https://www.cebm.net/index.aspx?o=5653" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.cebm.net/index.aspx?o=5653</a>.</cite>
</li>
<li id="ref012">
<span class="label">[12].</span><cite>Jadad AR, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials (1996;17(1):1–12.</cite> [<a href="https://doi.org/10.1016/0197-2456(95)00134-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8721797/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Control%20Clin%20Trials&amp;title=Assessing%20the%20quality%20of%20reports%20of%20randomized%20clinical%20trials:%20Is%20blinding%20necessary?&amp;author=AR%20Jadad&amp;volume=17&amp;issue=1&amp;publication_year=1996&amp;pages=1-12&amp;pmid=8721797&amp;doi=10.1016/0197-2456(95)00134-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref013">
<span class="label">[13].</span><cite>Lupski JR, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell. 1991;66(2):219–32.</cite> [<a href="https://doi.org/10.1016/0092-8674(91)90613-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1677316/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=DNA%20duplication%20associated%20with%20Charcot-Marie-Tooth%20disease%20type%201A&amp;author=JR%20Lupski&amp;volume=66&amp;issue=2&amp;publication_year=1991&amp;pages=219-32&amp;pmid=1677316&amp;doi=10.1016/0092-8674(91)90613-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref014">
<span class="label">[14].</span><cite>Raeymaekers P, et al. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul Disord. 1991;1(2):93–7.</cite> [<a href="https://doi.org/10.1016/0960-8966(91)90055-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1822787/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neuromuscul%20Disord&amp;title=Duplication%20in%20chromosome%2017p11.2%20in%20Charcot-Marie-Tooth%20neuropathy%20type%201a%20(CMT%201a).%20The%20HMSN%20Collaborative%20Research%20Group&amp;author=P%20Raeymaekers&amp;volume=1&amp;issue=2&amp;publication_year=1991&amp;pages=93-7&amp;pmid=1822787&amp;doi=10.1016/0960-8966(91)90055-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref015">
<span class="label">[15].</span><cite>Foley AR, et al. Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain. 2014;137(Pt 1):44–56.</cite> [<a href="https://doi.org/10.1093/brain/awt315" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3891447/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24253200/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Brain&amp;title=Treatable%20childhood%20neuronopathy%20caused%20by%20mutations%20in%20riboflavin%20transporter%20RFVT2&amp;author=AR%20Foley&amp;volume=137&amp;issue=Pt%201&amp;publication_year=2014&amp;pages=44-56&amp;pmid=24253200&amp;doi=10.1093/brain/awt315&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref016">
<span class="label">[16].</span><cite>Graham RC, Hughes RAC. A modified peripheral neuropathy scale: The Overall Neuropathy Limitations Scale. Journal of Neurology, Neurosurgery, and Psychiatry. 2006;77(8):973–6.</cite> [<a href="https://doi.org/10.1136/jnnp.2005.081547" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2077620/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16574730/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Neurology,%20Neurosurgery,%20and%20Psychiatry&amp;title=A%20modified%20peripheral%20neuropathy%20scale:%20The%20Overall%20Neuropathy%20Limitations%20Scale&amp;author=RC%20Graham&amp;author=RAC%20Hughes&amp;volume=77&amp;issue=8&amp;publication_year=2006&amp;pages=973-6&amp;pmid=16574730&amp;doi=10.1136/jnnp.2005.081547&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref017">
<span class="label">[17].</span><cite>
S.A., Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT) (PLEO-CMT). ClinicalTrials.gov, 2020.</cite>
</li>
<li id="ref018">
<span class="label">[18].</span><cite>Berk JL, et al. Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial. Jama. 2013;310(24):2658–67.</cite> [<a href="https://doi.org/10.1001/jama.2013.283815" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4139164/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24368466/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Jama&amp;title=Repurposing%20diflunisal%20for%20familial%20amyloid%20polyneuropathy:%20A%20randomized%20clinical%20trial&amp;author=JL%20Berk&amp;volume=310&amp;issue=24&amp;publication_year=2013&amp;pages=2658-67&amp;pmid=24368466&amp;doi=10.1001/jama.2013.283815&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref019">
<span class="label">[19].</span><cite>Aguirre MA, et al. Transthyretin-related hereditary amyloidosis in an Argentinian family with TTR Tyr114Cys mutation. Amyloid. 2017;24(sup1):102.</cite> [<a href="https://doi.org/10.1080/13506129.2017.1291422" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28434328/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Transthyretin-related%20hereditary%20amyloidosis%20in%20an%20Argentinian%20family%20with%20TTR%20Tyr114Cys%20mutation&amp;author=MA%20Aguirre&amp;volume=24&amp;issue=sup1&amp;publication_year=2017&amp;pages=102&amp;pmid=28434328&amp;doi=10.1080/13506129.2017.1291422&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref020">
<span class="label">[20].</span><cite>Smith CA, et al. Effects of exercise and creatine on myosin heavy chain isoform composition in patients with Charcot-Marie-Tooth disease. Muscle Nerve. 2006;34(5):586–94.</cite> [<a href="https://doi.org/10.1002/mus.20621" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16881064/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Muscle%20Nerve&amp;title=Effects%20of%20exercise%20and%20creatine%20on%20myosin%20heavy%20chain%20isoform%20composition%20in%20patients%20with%20Charcot-Marie-Tooth%20disease&amp;author=CA%20Smith&amp;volume=34&amp;issue=5&amp;publication_year=2006&amp;pages=586-94&amp;pmid=16881064&amp;doi=10.1002/mus.20621&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref021">
<span class="label">[21].</span><cite>Alnylam Pharmaceuticals I. A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02. EU Clinical Trials, 2017.</cite>
</li>
<li id="ref022">
<span class="label">[22].</span><cite>Limited FP. Safety and Efficacy of Orally Administered Fx-1006A in Patients with Familial Amyloid Polyneuropathy (FAP): A Phase II/III, Randomised, Double-Blind, Placebo-Controlled Study. EU Clinical Trials. 2009.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=EU%20Clinical%20Trials&amp;title=Safety%20and%20Efficacy%20of%20Orally%20Administered%20Fx-1006A%20in%20Patients%20with%20Familial%20Amyloid%20Polyneuropathy%20(FAP):%20A%20Phase%20II/III,%20Randomised,%20Double-Blind,%20Placebo-Controlled%20Study&amp;author=FP%20Limited&amp;publication_year=2009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref023">
<span class="label">[23].</span><cite>Norcliffe-Kaufmann L, et al. Hyperdopaminergic crises in familial dysautonomia: A randomized trial of carbidopa. Neurology. 2013;80(17):1611–7.</cite> [<a href="https://doi.org/10.1212/WNL.0b013e31828f18f0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3662326/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23553478/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Hyperdopaminergic%20crises%20in%20familial%20dysautonomia:%20A%20randomized%20trial%20of%20carbidopa&amp;author=L%20Norcliffe-Kaufmann&amp;volume=80&amp;issue=17&amp;publication_year=2013&amp;pages=1611-7&amp;pmid=23553478&amp;doi=10.1212/WNL.0b013e31828f18f0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref024">
<span class="label">[24].</span><cite>Alnylam Pharmaceuticals I. An Open-Label Study To Evaluate The Efficacy And Safety Of Revusiran In Patients With Transthyretin-Mediated Familial Amyloidotic Polyneuropathy With Disease Progression Post Orthotopic Liver Transplant. EU Clinical Trials 2018.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=EU%20Clinical%20Trials&amp;title=An%20Open-Label%20Study%20To%20Evaluate%20The%20Efficacy%20And%20Safety%20Of%20Revusiran%20In%20Patients%20With%20Transthyretin-Mediated%20Familial%20Amyloidotic%20Polyneuropathy%20With%20Disease%20Progression%20Post%20Orthotopic%20Liver%20Transplant&amp;author=I%20Alnylam%20Pharmaceuticals&amp;pages=2018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref025">
<span class="label">[25].</span><cite>Barroso FA, et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: Results up to 6 years. Amyloid. 2017;24(3):194–204.</cite> [<a href="https://doi.org/10.1080/13506129.2017.1357545" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28758793/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Long-term%20safety%20and%20efficacy%20of%20tafamidis%20for%20the%20treatment%20of%20hereditary%20transthyretin%20amyloid%20polyneuropathy:%20Results%20up%20to%206%20years&amp;author=FA%20Barroso&amp;volume=24&amp;issue=3&amp;publication_year=2017&amp;pages=194-204&amp;pmid=28758793&amp;doi=10.1080/13506129.2017.1357545&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref026">
<span class="label">[26].</span><cite>Benson MD, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):22–31.</cite> [<a href="https://doi.org/10.1056/NEJMoa1716793" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12611561/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29972757/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Inotersen%20Treatment%20for%20Patients%20with%20Hereditary%20Transthyretin%20Amyloidosis&amp;author=MD%20Benson&amp;volume=379&amp;issue=1&amp;publication_year=2018&amp;pages=22-31&amp;pmid=29972757&amp;doi=10.1056/NEJMoa1716793&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref027">
<span class="label">[27].</span><cite>Burns J, et al. Effect of oral curcumin on Déjérine-Sottas disease. Pediatr Neurol. 2009;41(4):305–8.</cite> [<a href="https://doi.org/10.1016/j.pediatrneurol.2009.04.030" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19748054/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pediatr%20Neurol&amp;title=Effect%20of%20oral%20curcumin%20on%20D%C3%A9j%C3%A9rine-Sottas%20disease&amp;author=J%20Burns&amp;volume=41&amp;issue=4&amp;publication_year=2009&amp;pages=305-8&amp;pmid=19748054&amp;doi=10.1016/j.pediatrneurol.2009.04.030&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref028">
<span class="label">[28].</span><cite>Chaya S, et al. The First Case of Riboflavin Transporter Deficiency in sub-Saharan Africa. Semin Pediatr Neurol. 2018;26:10–14.</cite> [<a href="https://doi.org/10.1016/j.spen.2017.03.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29961494/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Semin%20Pediatr%20Neurol&amp;title=The%20First%20Case%20of%20Riboflavin%20Transporter%20Deficiency%20in%20sub-Saharan%20Africa&amp;author=S%20Chaya&amp;volume=26&amp;publication_year=2018&amp;pages=10-14&amp;pmid=29961494&amp;doi=10.1016/j.spen.2017.03.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref029">
<span class="label">[29].</span><cite>Kohlschütter A, et al. A child with night blindness: Preventing serious symptoms of Refsum disease. J Child Neurol. 2012;27(5):654–6.</cite> [<a href="https://doi.org/10.1177/0883073811424799" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22156782/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Child%20Neurol&amp;title=A%20child%20with%20night%20blindness:%20Preventing%20serious%20symptoms%20of%20Refsum%20disease&amp;author=A%20Kohlsch%C3%BCtter&amp;volume=27&amp;issue=5&amp;publication_year=2012&amp;pages=654-6&amp;pmid=22156782&amp;doi=10.1177/0883073811424799&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref030">
<span class="label">[30].</span><cite>Burns J, et al. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: A randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol. 2009;8(6):537–44.</cite> [<a href="https://doi.org/10.1016/S1474-4422(09)70108-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19427269/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Neurol&amp;title=Ascorbic%20acid%20for%20Charcot-Marie-Tooth%20disease%20type%201A%20in%20children:%20A%20randomised,%20double-blind,%20placebo-controlled,%20safety%20and%20efficacy%20trial&amp;author=J%20Burns&amp;volume=8&amp;issue=6&amp;publication_year=2009&amp;pages=537-44&amp;pmid=19427269&amp;doi=10.1016/S1474-4422(09)70108-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref031">
<span class="label">[31].</span><cite>Adi T, et al. A novel gain-of-function Na(v)1. 7 mutation in a carbamazepine-responsive patient with adult-onset painful peripheral neuropathy. Mol Pain. 2018;14:1744806918815007–.</cite> [<a href="https://doi.org/10.1177/1744806918815007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6856981/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30392441/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=7%20mutation%20in%20a%20carbamazepine-responsive%20patient%20with%20adult-onset%20painful%20peripheral%20neuropathy.%20Mol%20Pain&amp;title=A%20novel%20gain-of-function%20Na(v)1&amp;author=T%20Adi&amp;volume=14&amp;publication_year=2018&amp;pages=1744806918815007&amp;pmid=30392441&amp;doi=10.1177/1744806918815007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref032">
<span class="label">[32].</span><cite>Alnylam Pharmaceuticals I. APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP). EU Clinical Trials 2018.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=EU%20Clinical%20Trials&amp;title=APOLLO:%20A%20Phase%203%20Multicenter,%20Multinational,%20Randomized,%20Double-blind,%20Placebo-controlled%20Study%20to%20Evaluate%20the%20Efficacy%20and%20Safety%20of%20Patisiran%20(ALN-TTR02)%20in%20Transthyretin%20(TTR)-Mediated%20Polyneuropathy%20(Familial%20Amyloidotic%20Polyneuropathy-FAP)&amp;author=I%20Alnylam%20Pharmaceuticals&amp;publication_year=2018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref033">
<span class="label">[33].</span><cite>Kapoor M, et al. Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis. J Neuromuscul Dis. 2019;6(2):189–99.</cite> [<a href="https://doi.org/10.3233/JND-180371" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6598024/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30829617/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neuromuscul%20Dis&amp;title=Clinical%20Presentation,%20Diagnosis%20and%20Treatment%20of%20TTR%20Amyloidosis&amp;author=M%20Kapoor&amp;volume=6&amp;issue=2&amp;publication_year=2019&amp;pages=189-99&amp;pmid=30829617&amp;doi=10.3233/JND-180371&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref034">
<span class="label">[34].</span><cite>Cortese A, et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat Genet. 2020;52(5):473–81.</cite> [<a href="https://doi.org/10.1038/s41588-020-0615-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8353599/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32367058/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Genet&amp;title=Biallelic%20mutations%20in%20SORD%20cause%20a%20common%20and%20potentially%20treatable%20hereditary%20neuropathy%20with%20implications%20for%20diabetes&amp;author=A%20Cortese&amp;volume=52&amp;issue=5&amp;publication_year=2020&amp;pages=473-81&amp;pmid=32367058&amp;doi=10.1038/s41588-020-0615-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref035">
<span class="label">[35].</span><cite>Juneja M, et al. Challenges in modelling the Charcot-Marie-Tooth neuropathies for therapy development. J Neurol Neurosurg Psychiatry. 2019;90(1):58–67.</cite> [<a href="https://doi.org/10.1136/jnnp-2018-318834" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6327864/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30018047/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol%20Neurosurg%20Psychiatry&amp;title=Challenges%20in%20modelling%20the%20Charcot-Marie-Tooth%20neuropathies%20for%20therapy%20development&amp;author=M%20Juneja&amp;volume=90&amp;issue=1&amp;publication_year=2019&amp;pages=58-67&amp;pmid=30018047&amp;doi=10.1136/jnnp-2018-318834&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref036">
<span class="label">[36].</span><cite>Micallef J, et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: A multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2009;8(12):1103–10.</cite> [<a href="https://doi.org/10.1016/S1474-4422(09)70260-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19818690/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Neurol&amp;title=Effect%20of%20ascorbic%20acid%20in%20patients%20with%20Charcot-Marie-Tooth%20disease%20type%201A:%20A%20multicentre,%20randomised,%20double-blind,%20placebo-controlled%20trial&amp;author=J%20Micallef&amp;volume=8&amp;issue=12&amp;publication_year=2009&amp;pages=1103-10&amp;pmid=19818690&amp;doi=10.1016/S1474-4422(09)70260-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref037">
<span class="label">[37].</span><cite>Verhamme C, et al. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: A randomised, double-blind, placebo-controlled phase II trial. BMC Med. 2009;7:70.</cite> [<a href="https://doi.org/10.1186/1741-7015-7-70" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2784478/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19909499/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Med&amp;title=Oral%20high%20dose%20ascorbic%20acid%20treatment%20for%20one%20year%20in%20young%20CMT1A%20patients:%20A%20randomised,%20double-blind,%20placebo-controlled%20phase%20II%20trial&amp;author=C%20Verhamme&amp;volume=7&amp;publication_year=2009&amp;pages=70&amp;pmid=19909499&amp;doi=10.1186/1741-7015-7-70&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref038">
<span class="label">[38].</span><cite>Lewis RA, et al. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: Results of a randomized, double-masked, controlled trial. JAMA Neurol. 2013;70(8):981–7.</cite> [<a href="https://doi.org/10.1001/jamaneurol.2013.3178" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3752369/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23797954/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Neurol&amp;title=High-dosage%20ascorbic%20acid%20treatment%20in%20Charcot-Marie-Tooth%20disease%20type%201A:%20Results%20of%20a%20randomized,%20double-masked,%20controlled%20trial&amp;author=RA%20Lewis&amp;volume=70&amp;issue=8&amp;publication_year=2013&amp;pages=981-7&amp;pmid=23797954&amp;doi=10.1001/jamaneurol.2013.3178&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref039">
<span class="label">[39].</span><cite>Attarian S, et al. Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A. ClinicalTrials.gov, 2014.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=ClinicalTrials.gov&amp;title=Phase%20II,%20Randomized,%20Placebo-controlled%20Trial%20in%20Patients%20With%20Charcot-marie-tooth%20Disease%20Type%201A&amp;author=S%20Attarian&amp;publication_year=2014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref040">
<span class="label">[40].</span><cite>Pareyson D, et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): A double-blind randomised trial. Lancet Neurol. 2011;10(4):320–8.</cite> [<a href="https://doi.org/10.1016/S1474-4422(11)70025-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3154498/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21393063/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Neurol&amp;title=Ascorbic%20acid%20in%20Charcot-Marie-Tooth%20disease%20type%201A%20(CMT-TRIAAL%20and%20CMT-TRAUK):%20A%20double-blind%20randomised%20trial&amp;author=D%20Pareyson&amp;volume=10&amp;issue=4&amp;publication_year=2011&amp;pages=320-8&amp;pmid=21393063&amp;doi=10.1016/S1474-4422(11)70025-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref041">
<span class="label">[41].</span><cite>Coelho T, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial. Neurology. 2012;79(8):785–92.</cite> [<a href="https://doi.org/10.1212/WNL.0b013e3182661eb1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4098875/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22843282/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Tafamidis%20for%20transthyretin%20familial%20amyloid%20polyneuropathy:%20A%20randomized,%20controlled%20trial&amp;author=T%20Coelho&amp;volume=79&amp;issue=8&amp;publication_year=2012&amp;pages=785-92&amp;pmid=22843282&amp;doi=10.1212/WNL.0b013e3182661eb1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref042">
<span class="label">[42].</span><cite>Kon T, et al. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: A case report. Amyloid. 2015;22(3):203–4.</cite> [<a href="https://doi.org/10.3109/13506129.2015.1031373" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26123280/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Effects%20of%20liver%20transplantation%20and%20tafamidis%20in%20hereditary%20transthyretin%20amyloidosis%20caused%20by%20transthyretin%20Leu55Pro%20mutation:%20A%20case%20report&amp;author=T%20Kon&amp;volume=22&amp;issue=3&amp;publication_year=2015&amp;pages=203-4&amp;pmid=26123280&amp;doi=10.3109/13506129.2015.1031373&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref043">
<span class="label">[43].</span><cite>Cortese A, et al. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: A longitudinal multicenter study in a non-endemic area. J Neurol. 2016;263(5):916–24.</cite> [<a href="https://doi.org/10.1007/s00415-016-8064-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26984605/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol&amp;title=Monitoring%20effectiveness%20and%20safety%20of%20Tafamidis%20in%20transthyretin%20amyloidosis%20in%20Italy:%20A%20longitudinal%20multicenter%20study%20in%20a%20non-endemic%20area&amp;author=A%20Cortese&amp;volume=263&amp;issue=5&amp;publication_year=2016&amp;pages=916-24&amp;pmid=26984605&amp;doi=10.1007/s00415-016-8064-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref044">
<span class="label">[44].</span><cite>Fujita T, et al. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report. Cardiology. 2017;137(2):74–77.</cite> [<a href="https://doi.org/10.1159/000455089" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28152524/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cardiology&amp;title=Tafamidis%20for%20the%20Treatment%20of%20Hereditary%20Transthyretin%20Amyloid%20Cardiomyopathy:%20A%20Case%20Report&amp;author=T%20Fujita&amp;volume=137&amp;issue=2&amp;publication_year=2017&amp;pages=74-77&amp;pmid=28152524&amp;doi=10.1159/000455089&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref045">
<span class="label">[45].</span><cite>Limited FP. The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients with Non-V30M Transthyretin Amyloidosis. EU Clinical Trials. 2016.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=EU%20Clinical%20Trials&amp;title=The%20Effects%20of%20Fx-1006A%20on%20Transthyretin%20Stabilization%20and%20Clinical%20Outcome%20Measures%20in%20Patients%20with%20Non-V30M%20Transthyretin%20Amyloidosis&amp;author=FP%20Limited&amp;publication_year=2016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref046">
<span class="label">[46].</span><cite>Bar-Aluma BE, et al. A Controlled Trial of Inhaled Bronchodilators in Familial Dysautonomia. Lung. 2018;196(1):93–101.</cite> [<a href="https://doi.org/10.1007/s00408-017-0073-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29234869/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung&amp;title=A%20Controlled%20Trial%20of%20Inhaled%20Bronchodilators%20in%20Familial%20Dysautonomia&amp;author=BE%20Bar-Aluma&amp;volume=196&amp;issue=1&amp;publication_year=2018&amp;pages=93-101&amp;pmid=29234869&amp;doi=10.1007/s00408-017-0073-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref047">
<span class="label">[47].</span><cite>Panosyan FB, Tawil R, Herrmann DN. Episodic weakness and Charcot-marie-tooth disease due to a mitochondrial MT-ATP6 mutation. Muscle Nerve. 2017;55(6):922–7.</cite> [<a href="https://doi.org/10.1002/mus.25453" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27783406/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Muscle%20Nerve&amp;title=Episodic%20weakness%20and%20Charcot-marie-tooth%20disease%20due%20to%20a%20mitochondrial%20MT-ATP6%20mutation&amp;author=FB%20Panosyan&amp;author=R%20Tawil&amp;author=DN%20Herrmann&amp;volume=55&amp;issue=6&amp;publication_year=2017&amp;pages=922-7&amp;pmid=27783406&amp;doi=10.1002/mus.25453&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref048">
<span class="label">[48].</span><cite>Perna A, et al. Severe 5,10-methylenetetrahydrofolate reductase deficiency: A rare. Treatable Cause of Complicated Hereditary Spastic Paraplegia. 2018;25(3):602–5.</cite> [<a href="https://doi.org/10.1111/ene.13557" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29284203/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Treatable%20Cause%20of%20Complicated%20Hereditary%20Spastic%20Paraplegia&amp;title=Severe%205,10-methylenetetrahydrofolate%20reductase%20deficiency:%20A%20rare&amp;author=A%20Perna&amp;volume=25&amp;issue=3&amp;publication_year=2018&amp;pages=602-5&amp;pmid=29284203&amp;doi=10.1111/ene.13557&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref049">
<span class="label">[49].</span><cite>Finsterer J, Regelsberger G, Voigtländer T. Refsum disease due to the splice-site mutation c.135-2A&gt;G before exon 3 of the PHYH gene, diagnosed eight years after detection of retinitis pigmentosa.  J Neurol Sci. 2008;266(1-2):182–6.</cite> [<a href="https://doi.org/10.1016/j.jns.2007.09.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17905308/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol%20Sci&amp;title=Refsum%20disease%20due%20to%20the%20splice-site%20mutation%20c.135-2A&gt;G%20before%20exon%203%20of%20the%20PHYH%20gene,%20diagnosed%20eight%20years%20after%20detection%20of%20retinitis%20pigmentosa&amp;author=J%20Finsterer&amp;author=G%20Regelsberger&amp;author=T%20Voigtl%C3%A4nder&amp;volume=266&amp;issue=1-2&amp;publication_year=2008&amp;pages=182-6&amp;pmid=17905308&amp;doi=10.1016/j.jns.2007.09.005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref050">
<span class="label">[50].</span><cite>Foley AR, et al. Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain. 2014;137(Pt 1):44–56.</cite> [<a href="https://doi.org/10.1093/brain/awt315" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3891447/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24253200/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Brain&amp;title=Treatable%20childhood%20neuronopathy%20caused%20by%20mutations%20in%20riboflavin%20transporter%20RFVT2&amp;author=AR%20Foley&amp;volume=137&amp;issue=Pt%201&amp;publication_year=2014&amp;pages=44-56&amp;pmid=24253200&amp;doi=10.1093/brain/awt315&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref051">
<span class="label">[51].</span><cite>Fridman V, et al. Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1. Neurology. 2019;92(4):e359–e370.</cite> [<a href="https://doi.org/10.1212/WNL.0000000000006811" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6345118/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30626650/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Randomized%20trial%20of%20l-serine%20in%20patients%20with%20hereditary%20sensory%20and%20autonomic%20neuropathy%20type%201&amp;author=V%20Fridman&amp;volume=92&amp;issue=4&amp;publication_year=2019&amp;pages=e359-e370&amp;pmid=30626650&amp;doi=10.1212/WNL.0000000000006811&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref052">
<span class="label">[52].</span><cite>Auranen M, et al. Clinical and metabolic consequences of L-serine supplementation in hereditary sensory and autonomic neuropathy type 1C. Cold Spring Harb Mol Case Stud. 2017;3(6).</cite> [<a href="https://doi.org/10.1101/mcs.a002212" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5701299/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29042446/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cold%20Spring%20Harb%20Mol%20Case%20Stud&amp;title=Clinical%20and%20metabolic%20consequences%20of%20L-serine%20supplementation%20in%20hereditary%20sensory%20and%20autonomic%20neuropathy%20type%201C&amp;author=M%20Auranen&amp;volume=3&amp;issue=6&amp;publication_year=2017&amp;pmid=29042446&amp;doi=10.1101/mcs.a002212&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>Supplementary Tables 1 and 3</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/8203235/bin/jnd-8-jnd200546-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">Click here for additional data file.</a><sup> (35.7KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="caption p"><span>Supplementary Table 2</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/8203235/bin/jnd-8-jnd200546-s002.csv" data-ga-action="click_feat_suppl" class="usa-link">Click here for additional data file.</a><sup> (23.9KB, csv) </sup>
</div></div></section></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Journal of Neuromuscular Diseases are provided here courtesy of <strong>IOS Press</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.3233/JND-200546"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/jnd-8-jnd200546.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.2 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/8203235/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/8203235/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC8203235%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC8203235/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC8203235/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC8203235/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/32773395/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC8203235/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/32773395/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC8203235/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/8203235/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="BjdOGBzufg9v0p6cY0mF2MZ1kbYMY6qjC20v9mXGcCo1kSpxcerlQqrB5ZemBG7X">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
